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The units, measurements and abbreviations of the unexplained scientific terms used in the 
current study are all listed in the glossary. The other abbreviations in the text are explained 











mM milli molar 
nM nano molar 
RPM rounds per minute 
s second 
pmol pico molar 
mW milli watt 




AKT AKT Serine/Threonine Kinase 
Approx. approximately 
AP1 Activator Protein 1 
ATP Adenosine triphosphate  
BCC Basal Cell Carcinoma 
BiP Binding Immunoglobulin Protein 
CRAC Calcium Release-Activated Channels 
ER Endoplasmatisches Retikulum 
ERo1 ER oxidase 1 
ERK Extracellular signal-Regulated Kinase 
HIF1α Hypoxia-inducible factor 1α 
IP3R Inositol trisphosphate Receptor 
MAM Mitochondria-Associated Membrane 
MAPK Mitogen-Activated Protein Kinase 
MCU Mitochondrial Calcium Uniporter 
MITF Microphthalmia-associated Transcription Factor 
NFAT Nuclear Factor of Activated T-cells 
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NF-κB Nuclear Factor kappa-light-chain-enhancer of activated B cells 
NMSC Non-Melanoma Skin Cancer 
NO Nitric Oxide 
NOX NAD(P)H oxidase 
RNS Reactive Nitrogen Species 
OCR Oxygen Consumption Rate 
OMM Out Mitochondria Membrane 
ORAI ORAI Calcium Release-activated Calcium Channel Protein 
OXPHOS Oxidative Phosphorylation 
PDI Protein Disulfide Isomerase 
PGC1α Peroxisome proliferator-activated receptor γ Coactivator 1 alpha 
PI3K Phosphatidylinositide 3-kinase 
PM Plasma membrane 
PMA Phorbol 12-myristate 13-acetate 
PMCA Plasma Membrane Ca2+ ATPase 
ROS Reactive Oxygen Species 
PTEN Phosphatase and tensin homolog 
PTP Permeability Transition Pore 
SCC Squamous Cell Carcinoma 
SKCM TCGA Skin Cutaneous Melanoma 
SOCE Sarco/endoplasmic reticulum Ca2+-ATPase 
STIM Stromal Interaction Molecule 
TMX Thioredoxin related transmembrane protein 
Trx Thioredoxin 
TXNDC15 Thioredoxin Domain Containing 15 
UPR Unfolded Protein Response 
CaV Voltage gated Ca2+ channel 







Melanom ist die tödlichste Form von Hautkrebs und trat mit steigender Prävalenz in den 
vergangenen Jahrzehnten auf. Bei der Entstehung und dem Verlauf dieser Krebserkrankung 
spielen reaktive Sauerstoff Spezies (ROS), sowie die Dysregulation von Signalwegen eine 
wichtige Rolle. Außerdem führen die oxidative Stressantwort, sowie die Aktivierung von 
alternativen Signalwegen häufig zu Behandlungsesistenzen und einem erhöhten 
Metastasierungspotential, was Auswirkungen auf das Patientenüberleben hat. Zahlreiche 
wissenschaftliche Arbeiten konnten den Einfluss von oxidativem Stress auf verschiedene 
Signalwege in Schwarzem Hautkrebs nachweisen. Diese Signalwege können auf der anderen 
Seite wieder zu einer veränderten ROS Produktion oder antioxidativen Kapazität führen. 
Daher kann das bessere Verständnis der Interaktion von ROS und Redoxregulation von 
Signalwegen neue Einblicke in Behandlungsmöglichkeiten geben und diese verbessern. 
Die Mitochondrien sind wichtige Zellorganellen, in denen durch oxidative Phosphorylierung 
ATP, sowie als molekulares Nebenprodukt ROS produziert werden. Durch die Nähe zum ER 
(Endoplasmatisches Retikulum) spielen Mitochondrien auch eine bedeutende Rolle in der 
Regulation von intrazellulärem Calcium und dem Feintuning nachfolgender Signalkaskaden. 
Es deutet viel darauf hin, dass Anomalien in den Mitochondrien, die im Mittelpunkt von 
Biogenese, Redoxregulation und Kontrolle von Signalwegen stehen, zur Melanomentstehung 
beitragen. Zusätzlich beeinflussen die Reprogrammierung, sowie Positionierung der 
Mitochondrien das Zellüberleben, sowie die Resistenzbildung gegenüber Therapien bei Krebs, 
eingeschlossen dem Melanom.  
Daher haben wir in diesem Zusammenhang untersucht, wie die Veränderung von 
Kontaktstellen zwischen Mitochondrien und ER durch TMX1 und TMX3, den 
Oxidoreduktasen in der Mitochondrien assozierten ER Membran (MAM), die Funktion der 
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Mitochondrien, von Zellsignale und die Melanom-Pathologie beeinflussen. In dieser Arbeit 
konnte gezeigt werden, dass TMX1, TMX3 und der Calcium/Calciumneurin-regulierte 
Transkriptionsfaktor NFAT1 im Vergleich zu Melanozyten und Keratinozyten in Melanom 
Zelllinien und Patientenproben überexprimiert sind. Der Knockdown von TMX1 und TMX3 
führte durch einen Anstieg an mitochondiralen ROS, sowie einer erhöhten NAD(P)H Oxidase 
4 (NOX4) Aktivität, zu einem Anstieg von ROS im Zytosol. Dadurch wurde die 
Translokation von NFAT1 in den Zellkern durch die Oxidation der Phosphatase Calcineurin 
verhindert. Durch die Inhibition der NFAT1-Aktivierung und die daraus folgende geringere 
transkriptionale Aktivität, wurde die Expression von Zielgenen beeinflusst.  Die Inhibition 
von NFAT1 verursachte schließlich eine Hemmung der Melanomproliferation, der Migration 
in vitro und des Tumorwachstums in vivo.  
Zusammenfassend lässt sich sagen, dass Mitochondrien-ER-Kontaktstellen die Melanom-
Redox-Homöostase regulieren und den Signalweg von Calcineurin-NFAT1 beeinflussen. 





Melanoma is the deadliest skin cancer with an increasing incidence in the past decades. The 
reactive oxygen species (ROS) and dysregulation of signaling pathways play important roles 
in the formation and progression of melanoma. Furthermore, the oxidative stress response and 
activation of alternative signaling pathways were reported as determinants of drug resistance, 
survival and metastasis of melanoma. There is abundant scientific literature demonstrating 
that the oxidative stress can influence multiple signaling pathways in melanoma and in return, 
the changes of these signaling pathways often lead to an altered ROS production or 
antioxidant capacity. Hence, understanding of the interaction between ROS and the redox 
regulation of signaling pathways could provide beneficial insights for treatment.  
Mitochondria are organelles wherein the oxidative phosphorylation produces ATP as well as 
ROS as byproducts. Due to the proximity to the endoplasmic reticulum (ER), mitochondria 
also play a critical role in the regulation of intracellular calcium and the fine-tuning of the 
calcium-controlled signal cascades. Therefore, there are culminating evidences suggesting 
that mitochondria act as hubs of biogenesis, redox regulation and calcium signaling thereby 
controlling cellular function. Anomalies in mitochondrial function contribute to 
carcinogenesis of melanoma. Additionally, the reprogramming and positioning of 
mitochondria were shown as important factors in controlling cell survival and resistance 
against treatment in cancer including melanoma.  
We investigated how the disturbance of contact sites between mitochondria and ER through 
manipulation of thioredoxin related transmembrane protein 1 (TMX1) and thioredoxin related 
transmembrane protein 3 (TMX3), oxidoreductases localized in the mitochondria-associated 
ER membrane (MAM) affect the mitochondrial function, cell signaling and melanoma 
pathobiology. In the present study, TMX1, TMX3 and a calcium/calcineurin-regulated 
transcription factor Nuclear Factor of Activated T-cells 1 (NFAT1) demonstrated up-
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regulated expression in the melanoma cell lines and patient samples compared with healthy 
melanocytes and keratinocytes. The knockdown of TMX1 and TMX3 resulted in an elevated 
ROS via mitochondria and NAD(P)H oxidase 4 (NOX4) and NFAT1 inhibition via oxidation 
of the phosphatase calcineurin. The inhibition of NFAT1 led to a lower NFAT1 
transcriptional activity, which affected expression of the target genes. Inhibition of NFAT1 
eventually caused a suppression of melanoma proliferation, migration in vitro and tumor 
growth in vivo.   
In conclusion, our study suggests that mitochondria-ER contact sites regulate melanoma 
redox homeostasis and influence calcineurin-NFAT1 signaling pathway. TMX and NFAT1 





5.1 Skin and melanoma pathology 
5.1.1 The human skin 
The human skin is the largest organ of the integumentary system, which covers the surface of 
the body and serves as the first line of defense against various types of damage, harmful fluids, 
radiation and pathogens. As depicted in Graph 1, the skin consists of three different layers, 
namely the epidermis, dermis and subcutis.  
The epidermis is the outer layer of the skin. It consists of three major cell types (keratinocytes, 
melanocytes and Langerhans cells), each of which has a different function. Keratinocytes are 
the predominant cell type in the epidermis; they produce keratin. They are developed from the 
stratum basale and migrate upwards to the stratum corneum after maturation. Dead 
keratinocytes in the corneum are constantly replaced by the new ones. Keratinocytes mainly 
function as a barrier against pathogens such as bacteria, viruses, parasites, fungi, ultraviolent 
(UV) radiation and dehydration. Melanocytes originate from the neural crest. They are 
responsible for melanin production and the pigmentation of the skin via their association with 
keratinocytes. In addition to melanin, they are able to produce signaling molecules such as 
cytokines, melanocortin peptides, catecholamines, serotonin and nitric oxide (NO) (1). 
Langerhans cells are dendritic cells responsible for cutaneous adaptive immune responses; 
they can promote CD4 T cell differentiation in a variety of inflammatory contexts (2). 
The epidermis and dermis are connected by a complex layer called the dermo-epidermal 
junction, which contains the basement membrane. The dermis is located beneath the 
epidermis; it contains fibers composed of collagen and elastin proteins, as well as the gel-like 
extracellular matrix. The most important cells in the dermis are the fibroblasts, which produce 
collagen, elastin and other molecules. The sebaceous glands, sweat glands, hair follicles, some 
nerves and muscle cells are also embedded in the dermis. The bottom layer is the subcutis, 
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which is comprised of a collagen fiber network, adipocytes, blood and lymphatic vessels and 
nerves. The subcutis provides additional protection against external stresses such as 
mechanical force or coldness. With regard to the formation of melanoma, the epidermis and 
dermis, as the outer layers, are directly exposed to carcinogens. As a result, melanomas 
develop from the melanocytes in the basement layer. 
 
Graph 1: Anatomy of the Human Skin. (Adapted from the University of California San 
Francisco/Melanoma Surgery/Department of Surgery; the link is as follows: 
https://melanoma.surgery.ucsf.edu/conditions--procedures/melanoma.aspx) 
 
5.1.2 Types of skin cancer and melanomas 
Based on their origins, skin cancers are generally categorized as being either non-melanoma 
skin cancers (NMSCs) or melanomas. Non-melanoma skin cancers develop from the basal 
cells and squamous cells in the epidermis, while melanomas originate from melanocytes 
derived from the neural crest. Melanomas and NMSCs are the most common types of cancer 
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in the fair-skinned population (3-5). About 80% of all NMSC are basal cell carcinomas, while 
squamous cell carcinomas account for approximately 20%; the other types only present 
around 1% of the diagnosed population (6).  
There are four basic melanomas: superficial spreading melanomas, nodular melanomas, 
lentigo maligna melanomas and acral lentiginous melanomas. The common melanomas are 
generally cutaneous (7). The superficial spreading melanoma is the most common type, it 
tends to radial growth and covers the surface of skin. The thickness of superficial spreading 
melanomas is usually around 1 mm, but they can grow vertically and penetrate the skin. 
Nodular melanomas are characterized by rapid growth and invasiveness; they appear on the 
skin surface but can penetrate into the deeper layers very swiftly. Lentigo maligna melanomas 
are usually found in older populations as a result of long-term sun exposure, and the 
histological characteristic of it is the proliferation of atypical melanocytes at the dermo-
epidermal junction. They are less aggressive compared to the other types of melanoma 
because they usually remain on the skin surface. When such a melanoma becomes invasive, it 
is termed a lentigo maligna melanoma (8). Acral lentiginous melanomas are common among 
Africans and Asians; they mainly develop on the feet or hands or under the nails. There are 
also several other types of melanoma, including amelanotic, polypoid and desmoplastic, but 
these are rarer and present in less than 5% of all cases. The staging of all melanomas is 
usually based on the thickness of tumor, ulceration status, the status of regional lymph node 
metastasis and distant metastasis. Further staging is usually based on information obtained 
from molecular diagnosis and biopsy.  
5.1.3 Risk factors for carcinogenesis of NMSCs and melanomas 
With regard to the pathogenesis of NMSCs and melanomas, the risk of incidence depends on 
both the health status of the host and environmental factors. In terms of environmental factors, 
increased exposure to sunlight, namely photocarcinogenesis, is considered a major causal 
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factor for both types of skin cancer (5, 9-12). Chronic or intermittent sun exposure can lead to 
sunburn or skin lesions, which can develop into skin cancers (13, 14). Although the 
relationship between patterns of sun exposure and the formation of skin cancer is complicated 
(15, 16), it is generally agreed that UV irradiation from sunlight is the main risk factor. This 
conclusion has been drawn based on several different observations. Epidemiological studies 
have demonstrated that the incidence and mortality rates of NMSCs and melanomas are 
negatively correlated to geographic latitude of residence. Based on mouse experiments, skin 
cancer can be induced by UV irradiation. The UVB spectrum (280–320 nm) is particularly 
carcinogenic, while the contribution of UVA is less clear (17), and UVC rays are usually 
blocked by the ozone layer and the atmosphere. Furthermore, the deficiencies of UV-induced 
DNA damage repair increase susceptibility to skin cancer (18).  
Ultraviolet irradiation-induced DNA damage is the critical initiating event for both NMSCs 
and melanomas. Such damage produces cyclobutane pyrimidine dimers which cause further 
DNA lesions and mutations as a result of errors in nucleotide excision repair (17, 19). 
Eventually, such mutations can lead to the activation of oncogenes or the silencing of tumor-
suppressor genes and prompt a malignant transformation (20, 21). However, the driving 
mutations for NMSCs and melanomas differ. In the BCC, Patched and Smoothened in the 
Sonic hedgehog pathway are prevalent, while, in the SCC, the driver genes are TP53, 
epidermal growth factor receptor (EGFR), cyclin-dependent kinase 2A (CDKN2A), tyrosine 
kinase Fyn (FYN) and rat sarcoma (RAS) (22). A melanoma exhibits markedly basal 
mutation rates induced by UV irradiation, which are caused by the accumulation of cytidine to 
thymidine transitions (23, 24). Mutations of TP53 and CDKN2A have also been found to be 
inducible by UV in melanomas. Beyond DNA damage, UV irradiation can also cause sunburn, 
inflammation, immune suppression and ROS generation in the skin and elevate the risk of 
skin cancer (25). 
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From a host’s perspective, there are many factors that can contribute to the carcinogenesis of 
NMSC or melanoma, including genetic heritage, age and phenotype characteristics. It is 
estimated that 5 to 12% of the worldwide incidence of melanomas can be attributed to 
inherited germline mutations (26, 27). The inheritance of melanoma is often observed in 
populations with lower risk susceptibility genes, but 5 to 10% of melanomas occured in 
families prone to melanoma, which indicates that high penetrance susceptibility genes are also 
important (28, 29). The hereditary melanomas are linked to autosomal-dominant disorders; 
the associated genetic alterations include CDKN2A, CDK4 (cyclin-dependent kinase 4), the 
telomerase complex proteins telomerase reverse transcriptase (TERT), protection of telomeres 
1, BRCA1-associated protein-1 (BAP1), microphthalmia-associated transcription factor 
(MITF), TP53, phosphatase and tensin homolog (PTEN) and xeroderma pigmentosum (XPA) 
(27, 30-36). The prevalence of these mutations in hereditary melanomas varies, but, generally, 
the risk of melanoma incidence for bearers is higher when compared to that of common 
individuals. Clinical surveillance is thus suggested on different degrees for the mutation 
bearers.  
The phenotypic characteristics of a host, such as hair color, eye color, skin color and freckle 
density, are often investigated in cohort studies or meta-studies (37-40) for the purpose of 
evaluating melanoma risk. However, these factors are very interactive with environmental 
factors; for example, freckle density, red or blond hair, blue eyes and light skin are the 
phenotypes related to photosensitivity. This means that bearers have a greater sensitivity to 
UV irradiation, which is in turn associated with a higher risk of skin cancer (41, 42). The 
cause of these phenotypes is the amount and type of cutaneous melanin generated by the 
bearer (43, 44); thus, controlling genes such as melanocortin-1 receptor plays a critical role in 
the development of melanomas in the subpopulation bearing these phenotypes (45, 46). 
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Beyond the phenotypic characteristics, the nevi number is another important reference for the 
evaluation of melanoma risk. The melanocytic nevi are benign neoplasms or hematomas 
composed of melanocytes. They can be acquired over the course of an individual’s lifetime or 
may be congenital, meaning that they developed during embryogenesis. As a risk factor, 
melanocytic nevi are generally associated with sun exposure, subpopulations with certain 
phenotype characteristics and bearers’ genetic predispositions, so multiple approaches to 
categorization and parameters are applied in the studies regarding the evaluation of nevi and 
melanoma occurrence. According to case-control studies on patients and meta-studies on 
melanoma risk, melanocytic and atypical naevi are also very prominent risk factors, a finding 
that could be used for the prediction of malignant melanomas (47, 48). The total numbers of 
common naevi and clinically atypical naevi are often two important parameters for analysis 
(49), while a large number of acquired melanocytic nevi is often considered as representing a 
high risk for melanoma, as it may indicate a higher genetic tendency towards melanoma 
formation or high exposure to environmental agents. Acquired nevi on soles, palms and nail 
have been found to be less dangerous (49, 50). As atypical naevi are usually larger and have a 
more variegated appearance when compared with the common naevi, they may conceal an 
underlying dysplasia, which could lead to melanoma formation. Dysplastic melanocytic nevi 
and non-dysplastic nevi demonstrate different degrees of risk compared the familial or non-
familial melanoma (51-54). Populations with familial melanomas and more atypical naevi are 
at much higher risk, while the estimation for populations without familial history of 
melanoma is usually lower. 
In general, past studies on host-related risk factors have demonstrated a good degree of 
standardization, which led to variations in their results. The heterogeneity in the methods of 
determination used also affected the estimations of risk factors; thus, the assessment of these 
studies needs further effort in order to increase the accuracy for the prediction. The etiology 
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of melanoma is complex; thus, researchers are in agreement that environmental and host 
factors such as phenotype characteristics and naevi or dysplastic naevi counts are inter-related, 
which may have caused the inconsistencies in the previous studies. The genetic understanding 
of the formation of melanomas remains incomplete, but further exploration may provide 
important clues for explaining these risk factors. 
5.1.4 Epidemiology of melanoma 
Non-melanoma skin cancers represent 5.8% of cancers from all sites and cause 0.7% of 
cancer-related deaths; the global estimation for 2018 was approximately 1 million new cases 
and 65,000 deaths, with most of these cases being related to BCC and SCC; melanomas 
represent only 1.6% of all new cases but cause 0.6% of all deaths, which are around 60,000 
new cases in 2018 (55). Malignant melanomas represent only about 5% of skin cancer 
diagnoses but account for more than 90% deaths associated with cutaneous tumors (56). 
Cutaneous melanomas account for more than 90% deaths of all melanoma cases (7, 57) and 
are considered to be the most rapidly increasing cancer in the white population. Globally, the 
incidence of melanoma has been increasing alarmingly over the past decades; in particular, 
the incidence rate of cutaneous melanoma was greater than that of any other malignancy (58). 
From 1970 to 2000, the incidence rates of melanoma increased approximately threefold in the 
United States and central Europe (4, 59-61), accompanied by a low level increase in mortality 
rates.  
Because of the genetic backgrounds of various populations and differences in sun exposure 
correlated to distance from the equator, there is significant geographic variation in the 
incidences of NMSCs and melanomas globally. The highest rates for NMSCs and melanomas 
were reported in Australia and New Zealand (at 37 cases per 100,000 people), followed by 
Northern America and Western Europe; the lowest were in South-Central Asia (55, 62). A 
major explanation is the different genetic background of populations, as white populations 
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have the highest incidence rate, while Asian and African populations have significantly lower 
incidence rates; however, registration system and diagnosis criteria could also affect the 
validity of these statistics. In Europe, the melanoma incidence rate is less than 10~25 new 
cases per 100,000 inhabitants; Switzerland has the highest rates and Greece the lowest. 
According to some studies, there is also a gradient of NMSC and melanoma incidence and 
mortality from northern to southern and western to eastern Europe (61, 63), which has been 
suggested as correlating with the distribution of various ethnic groups and the level of 
development in these countries. In the United States of America, the incidence rate is 20~30 
per 100,000 inhabitants; in Australia, the incidence is 50~60 per 100,000 inhabitants, which is 
the highest incidence recorded. With regard to mortality, Australia and New Zealand have the 
highest global melanoma mortality rates of around 3.5 per 100,000, while the rates in North 
America and Europe are 1.7 per 100,000 and 1.5 per 100,000, respectively (64, 65).  
The age demographics of melanoma are quite particular when compared with other cancers. 
Melanomas affect more of the younger population between 20 to 40 years compared with the 
other cancers which are usually found in the older population up to 60 years. The median age 
of diagnosis for melanoma is around 57 years, but incidence rates start to increase from 30 
years of age; around 50% of melanoma cases involve patients under 55 years of age, while 
approximately 30% occur among patients younger than 45 years. Incidences in populations 
under the age of 15 years are rare, but early over-exposure to UV is correlated with incidence 
in later life. In addition, the types of melanoma diagnosed in populations of different ages also 
display certain trends: Tumors among younger populations are less thick, while, in older 
populations, tumors are more often found on body parts that have been subjected to chronic 
exposure to sunlight and often are acral lentiginous or lentigo maligna types (3, 66). Those 
age-cohort studies that have attempted to explain these trends in melanoma incidence are 
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usually population dependent. In addition, the models used are generally difficult to interpret 
and fully fit to the clinical data on both incidence and mortality (61).  
The differences in incidence rates of NMSCs and melanomas between the gender groups are 
age dependent, and the overall incidence rates for men are two times higher than for women, 
as are mortality rates. Generally, the incidence of melanoma is higher in female populations 
under the age of 50, but the incidence in men over 60 years increases sharply. The overall 
mortality rates are higher for men than for women due to the late presentation of the disease 
and poor diagnosis in older populations.  
In general, epidemiological studies on melanoma have indicated an increasing trend in terms 
of incidence rates whereas mortality rates remained steady. Treating melanomas and NMSCs 
may represent a severe burden for healthcare systems in areas of high incidence. Thus, while 
research on the molecular basis of melanomas is challenging, it has the potential to yield 
results that are both of scientific and practical.  
 
5.2 Calcium signaling in melanoma 
5.2.1 Calcium signaling in cancer 
The calcium ions are one of the most important second messenger molecules. They impact 
many aspects of physiological functions, including muscle contraction, neural signal 
transmission and immune cell activation. On the cellular level, Ca2+ ions are involved in the 
proliferation, migration, apoptosis gene transcription and control of signaling pathways (67). 
Because of this multi-faceted role played by calcium, the intracellular Ca2+ concentration is 
under stringent maintenance which limits the free cytosolic Ca2+ concentration to 
approximately 100 nM whereas the extracellular environment has a concentration of 
approximately 1-2 mM (68). Cytosolic Ca2+ is mainly controlled by three seperate 
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mechanisms. First, the compartments in the cytosol, such as ER and mitochondria, can take 
up and release Ca2+. Second, the channels and pumps on the plasma membrane, such as the 
calcium release-activated channels (CRAC) and plasma membrane Ca2+ ATPases (PMCA), 
can control the entry and extrusion of Ca2+. Finally, cellular proteins such as calmodulin, 
which have a broad variety of affinities, can chelate Ca2+. Thus, the universal mechanism for 
Ca2+ signaling is the entry of calcium via the plasma membrane or the release of calcium from 
intracellular stores. Entry through plasma membrane or release of calcium from stores leads to 
the elevation of the cytosolic Ca2+ level and Ca2+ binding to proteins, which could further 
activate downstream effectors such as transcription factors and enzymes and lead to 
physiological changes. In addition, dysfunctions in calcium signaling can cause many 
pathological states, including cancer. The changes observed in calcium signaling in cancer 
cells usually include increased stimulated Ca2+ influx, sustained Ca2+ oscillations, lower basal 
Ca2+ and up-regulated SOCE, all of which can alter cell proliferation, intercellular 
communication and cell migration and promote resistance to apoptosis and oxidative stress 
(69-71). The cause of such alterations is often the irregular expressions of key components in 
the calcium pathways (72), such as PMCA (73-75), STIM (Stromal Interaction Molecule) 
/ORAI (ORAI Calcium Release-activated Calcium Channel Protein) (76-78) or the transient 
receptor potential (TRP) channels (79, 80). There are also studies that have suggested that the 
deregulation of intracellular Ca2+ stores, mitochondria and ER is responsible for the evasion 
of apoptosis in cancer cells (81).  
5.2.2 The role of calcium signaling in melanoma pathogenesis 
While the involvement of abnormal calcium signaling in melanoma pathology is indisputable 
as well as for the other malignancies, the key molecular players that affect melanoma 
pathology and underlying mechanisms remain to be identified in the field of melanoma 
research. Within the healthy human epidermis, a steep Ca2+ gradient is maintained. The Ca2+ 
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level in the basal layer is relatively low, but it progressively increases towards the outer layer. 
The Ca2+ level is highest in the stratum granulosum and drops to a minimum in the stratum 
corneum. The Ca2+ gradient is determined by the Ca2+ uptake and release of keratinocytes. 
This Ca2+ gradient promotes the sequential differentiation of keratinocytes as they migrate 
from the bottom to the outer layer of the epidermis to form the impermeable barrier of the 
skin. Thus, calcium signaling plays an important role in cell adhesion, cell-to-cell 
communication and the intracellular signaling of keratinocytes. Since keratinocyte 
differentiation is crucial to the formation of an intact epidermal barrier, the disruption of the 
epidermal barrier is involved in the development of diseases, including BCC and SSC. In the 
epidermis, the keratinocytes work with the neighboring melanocytes to produce photo-
protective melanin from the unique organelle melanosome, which is found in melanocytes. 
Through their interactions with keratinocytes, the proliferation, adhesion and migration of 
melanocytes are controlled (82, 83).  
Melanomas derive from the melanocytes or their progenitor cells in the basal layer of the 
epidermis. The developments of melanomas reflect an interdependence between 
environmental and host factors; it is a result of causal mutation and the consequent 
dysregulation of signaling pathways. The Clark model of melanoma progression (depicted in 
Graph 2) describes the histological features that can be identified during the transformation of 
normal melanocytes into a malignant melanoma (84). On the molecular level, the concomitant 
multi-step mutations are critical contributors to this progression. In the first phase of the Clark 
model, the abnormal proliferation of melanocytes, which is caused by the exclusive somatic 
mutation of NRAS or BRAF, results in the activation of the ERK-MAPK pathway, leading to 
the formation of benign nevi. The growth of benign nevi is suppressed by the senescence 
which is controlled by the expression of INK4A. In the next phase, the melanoma cells 
acquire the mutation of CDKN2A, PTEN, P53 or MITF amplification (85, 86). The 
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deactivation of tumor-suppressor genes and increased expression of the oncogene lead to 
aberrant cell proliferation, DNA repair, susceptibility to cell death and the development of 
dysplastic nevi from benign nevi. Eventually, the alteration of the wingless-type mammary 
tumor virus integration-site family (WNT) pathway disrupts the association of E-cadherin and 
β-catenin. The loss of E-cadherin, the expression of N-cadherin and aberrant ɑVβ3 integrin 
further decrease the adhesion of melanoma cells, which leads to the metastasis of the 
melanoma (87). As a universal second messenger molecule, Ca2+ is involved in many of these 
signaling pathways. For example, the activation of mitogen-activated protein kinase (MAPK) 
and WNT can be triggered by a calcium influx (88, 89), and downstream extracellular signal-
regulated kinase (ERK) is also regulated by calcium (90). In addition, important downstream 
transcription factors such as microphthalmia-associated transcription factor (MITF), NF-κB 




Graph 2: Biologic Events and Molecular Changes in the Progression of Melanoma. 
(Adapted from Arlo J. Miller and Martin C. Mihm, N Engl J Med 2006; 355:51-65.) 
 
Along with its role, the basic questions concerning the involvement of Ca2+ signaling are as 
follows: 1) Are there any differences in Ca2+ signaling between melanocyte and melanoma 
cells? 2) How does Ca2+ signaling contribute to the progression of melanoma? 3) Which Ca2+ 
signaling pathways are involved? Many efforts have been made to answer these questions in 
recent decades. In the early 1980s, researchers found that the calcium chelator EGTA, and 
voltage-gated Ca2+ channels (CaV), can affect the proliferation and migration of melanoma 
cells and thus established the first link between Ca2+ signaling and melanoma (93). However, 
this did not exclude the possibility of the involvement of other channels (94). Allen and 
colleagues subsequently characterized the ion channels in four different human melanoma cell 
lines and concluded that the melanoma cell lines displayed different patterns of ion channel 
expression, including calcium channels such as CRAC and CaV (95). The transient receptor 
potential (TRP) channels, especially melastatin 1 (TRPM1), were found to be regulated by the 
transcription factor MITF in melanocytes and melanoma; TRPM1 has a lower expression in 
primary melanoma and was originally identified as a metastasis suppressor (96-99). The 
research on murine melanoma line B16 revealed that the expression of melastatin is inversely 
correlated to the metastatic potential of these melanoma cells (97, 98). The TRPM channels 
belong to a superfamily of up to 30 members that can transport Ca2+, Mg2+ and Na2+. In 
addition to TRPM1, several other family members have been identified as functional in 
keratinocytes, melanocytes and melanoma. TRPV1, TRPV3, TRPV4 and TRPA1 are 
involved in the control of keratinocyte differentiation, inflammation response and hair growth 
(100-102); the TRPA1 and TRPML3 channels have also been found to be functional in 
melanocytes and melanoma cells (103, 104). To date, TRPM1 is generally agreed as the 
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channel required for melanin synthesis in melanocytes and cancer marker for the melanoma 
progression (105).  
With regard to cytosolic Ca2+ homeostasis, the CRAC channels are the determinant factors. 
The STIM and ORAI isoforms are important regulators in both normal and tumor tissue (106, 
107). While there are multiple isoforms of both, namely STIM1, STIM2, ORAI1, ORAI2 and 
ORAI3, the expression of the isoforms determines the SOCE response in different cells (108), 
and the amplitude of SOCE is determined by the relative expression of STIM and ORAI in 
such contexts (109). The first report on SOCE from melanoma cells was based on the findings 
that sustained SOCE could activate the protein kinase B/Akt signaling pathways, thus control 
proliferation of B16 melanoma cells, providing apoptosis resistance (110). This study features 
the mitochondria as the critical buffering pool to SOCE for keeping the ORAI channels open 
and maintaining robust Ca2+ entry since the expression of STIM1/ORAI is on the same level 
in both non-malignant and malignant B16 cells. The STIM and ORAI isoforms were also 
investigated in primary human melanocytes (111); and the study found that STIM2 and 
ORAI1 are the predominant isoforms expressed, and that SOCE controls endothelin-1-
induced melanin production. This study also indicated that STIM and ORAI could potentially 
regulate the pigmentation of skin upon UV radiation; they thus play an important role in 
adaptive tanning, which is protective against skin lesions by UV irradiation. The same authors 
also examined the contribution of STIM and ORAI in human melanoma cells (112), finding 
that STIM2/ORAI-controlled SOCE is a critical factor in melanoma phenotype switching. 
The silencing of STIM2/ORAI1 could increase the MITF expression and proliferation of 
melanoma cells, but it reduces their potential for migration. Therefore, STIM2/ORAI1 could 
be pharmacologically targeted to limit the invasion and metastasis of melanoma. Further 
studies have found that SOCE regulates the proliferation and migration of melanoma via the 
Extracellular signal-Regulated Kinase (ERK) signaling pathway, which provides the link 
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between SOCE and MAPK signaling in melanomas (113). Other recent studies have 
identified different mechanisms with regard to SOCE and melanoma invasion. 
STIM1/ORAI1-mediated Ca2+ oscillations have been found to promote melanoma invasion by 
affecting invadopodium assembly and extracellular matrix (ECM) degradation (114). Finally, 
Soboloff and colleagues found that WNT5A controls protein kinase C-mediated 
phosphorylation and SOCE in invasive melanoma, which provides another clue as to the 
function of STIM/ORAI (115). Taken together, these studies highlight the heterogeneity of 
SOCE in melanoma, but they all provide important knowledge regarding melanoma 
proliferation and migration. 
In summary, with regard to the role of calcium signaling in melanocytes and melanoma, the 
findings of previous studies provide important evidence and make it possible to identify 
interesting implications. However, due to the dynamic nature of calcium signaling and its 
complexity, additional research is required to fully answer the questions concerning the 
mechanisms and their potential use in therapeutics. 
 
5.3 Redox signaling in melanoma 
5.3.1 Redox signaling in cancer 
The reactive oxygen species (ROS) are unstable and bio-reactive species containing oxygen, 
including superoxide anion (O2-), hydrogen peroxide (H2O2) and hydroxyl radicals (OH-). 
They were considered as the byproducts from aerobic metabolism from mitochondria in the 
cells. These molecules have different physical and chemical properties that allow them to 
react with various biological targets, including lipids, DNA and proteins. Thus, ROS were 
considered as the damaging factors in cells (116). However, in recent decades, it has become 
apparent that ROS molecules can also serve as signals for regulating physiological and 
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pathological processes (117-119). The cysteine residues in the proteins exist in the form of 
thiolate anion, which is susceptible to oxidation; thus, the reversible oxidation of the thiol 
group serves as a biological function “switch” and a signal transduction mechanism (120-122).  
In cancer cells, the constitutive activation of signaling pathways related to proliferation leads 
to higher levels of bio-synthesis and energy metabolism. As a consequent of abnormal 
metabolic activity, cancer cells usually generate more ROS from mitochondria, ER or the 
NADPH oxidases (123, 124), which leads to a markedly higher intracellular ROS level 
compared to that of normal cells (70). Therefore, it was proposed that an elevated ROS level 
causes DNA damage and genomic instability, which could lead to tumorigenesis. In addition, 
it was found that, in some cancer cells, the ROS are essential for proliferation, migration and 
survival. The widely accepted explanation of it is that the important signaling pathways in 
these cell can be activated by ROS molecules (125-128). Furthermore, to control their redox 
balance, cancers prompt a higher antioxidant activity (129, 130), which could be targeted for 
therapeutic purposes (131, 132). Thus, there are many drugs that are designed to affect the 
redox homeostasis or ROS-regulated signaling pathways to either eliminate cancer cells or 
sensitize them to other therapeutic measures. The main methods used to achieve such ends 
include 1) artificially inducing the generation of ROS, 2) depleting intracellular antioxidant 
pools such as GSH and NADPH, 3) inhibiting critical enzymes such as SOD, thioredoxin, 
NADPH oxidases and 4) manipulating ROS-related signaling pathways.  
5.3.2 Redox signaling in melanocytes and melanoma 
Due to the complexity of their functions, ROS also play distinct roles in various aspects of 
melanoma development, including 1) melanomagenesis, 2) melanoma progression and 
metastasis and 3) therapeutic resistance.  
Upon UV exposure, melanocytes produce melanin through a series of chemical reactions 
based on the precursor L-tyrosine. The end products are either eumelanin or phaeomelanin, 
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which determine skin and eye color. The biosynthesis of phaeomelanin requires glutathione; 
thus, UV-induced production of phaeomelanin may compete with the antioxidant system for 
GSH and cause oxidative stress. Furthermore, under normal physiological condition, melanin 
protects the skin from UV and oxidative stress (133), but, in the presence of iron, 
phaeomelanin and the intermediate product S-cystainyldopa can also serve as prooxidants in 
melanoma cells. The oxidized melanin can react with O2 to form H2O2 and other radicals; 
therefore, the synthesis of melanin can produce ROS and disturb homeostasis, and this likely 
contributes to oxidative stress-induced genome instability and the malignant transformation. 
Another source of ROS in melanocytes is UV-radiation-induced inflammation; phagocytic 
cells can produce both ROS and reactive nitrogen species (RNS) from the respiratory burst, 
and phagocytes can invade the tissue and release H2O2. Despite its potential to cause 
inflammation and DNA damage, UV radiation can result in an impaired antioxidant defense. 
According to some studies, UV radiation suppresses the enzymatic activity of catalase, 
glutathione reductase and SOD in skin cells (134-136). It has been reported that UVA 
radiation upregulates the expression of thioredoxin-interacting protein which inhibits the 
scavenging activity of thioredoxin and promotes melanoma intravasation (137). Thus, by 
weakening antioxidants, UV radiation can also cause an elevation of intracellular ROS level. 
To eliminate the detrimental effect of UV exposure and the bio-synthesis of melanin, cells 
require a more active antioxidant system; however, this, in turn, could also enhance cell’s  
resistance to apoptosis and lead to a high stress tolerance, which could cause neoplastic 
transformation (138, 139). To eliminate the elevated ROS, cells of melanocytic origin have a 
higher antioxidant capacity when compared with keratinocytes (140). In primary melanomas, 
the expression of SOD and catalase is higher than in the normal skin and nevi (141, 142), 
which contributes to the resistance against internal oxidative stress. The third source of ROS 
involved in melanoma formation is related to the abnormal mitochondrial metabolic activity; 
in a fraction of melanoma cells, the oxidative phosphorylation (OXPHOS) is upregulated. 
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High level of mitochondrial respiration leads to excessive ROS generation, while drug 
resistance is also increased (143).  
With regard to the progression of melanoma, ROS mainly serve as the signaling molecules 
influencing the major pathways for the regulation of proliferation, metastasis, angiogenesis, 
immune escape, microenvironment manipulation and stress resistance (140, 144). The 
constitutively activated MAPK signaling in melanomas via mutated BRAF is a key modulator 
of melanoma initiation and progression; furthermore, it can regulate ROS production and 
coordinate with P53 to suppress apoptosis (145). The downstream serine/threonine kinase Akt 
activated via MAKP signaling can decrease the activity of phosphatase and tensin homolog 
(PTEN), which results in the attenuation of the antioxidant network in a melanoma (146). 
Furthermore, it has been found that Akt can induce the expression of NOX4 in a melanoma 
and that the produced ROS contribute to metastasis (147).  
As mentioned previously, the NF-κB signaling pathway is critical for cell survival and 
apoptosis control. In melanoma, anomalous NF-κB signaling has been found to be related to 
the intracellular H2O2, and the recruitment of co-activator AP-1 is correlated to the 
intracellular O2-. Together the activation of this pathway contributes to increased apoptosis 
resistance in melanomas (148). In addition, ROS generated by NAD(P)H oxidase (NOX) can 
also activate the NF-κB to enhance the proliferation of melanomas (149). The chemokines 
produced by the activation of NF-κB can also lead to the autonomous growth and invasion of 
melanoma cells by autocrine and paracrine signals. AP-1 regulates the expression of matrix 
metalloproteinases (MMPs) 1 and 2 (150, 151); thus, together, the activation of NF-κB and 
AP-1 by ROS could contribute to melanoma progression by enhancing the potential for 
migration and invasion of melanomas.  
Since ROS generation is higher in melanoma cells and they utilize an upregulated antioxidant 
system to control the redox balance, common strategies for targeted therapy are to induce 
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additional ROS generation or to inhibit the antioxidants with drugs. Buthionine sulfoximine 
(BSO), disulfiram (DSF) and 2-methoxyestradiol (2-ME2) were used in preclinical models to 
inhibit the endogenous antioxidants in melanoma (152-155). Both BSO and DSF have been 
used to manipulate the GSH pool, while DSF can also generate O2- and induce apoptosis. 2-
ME2 was tested in a mouse model for inhibiting SOD activity (156). It was found to have a 
strong anti-angiogenic effect, which leads to the inhibition of tumor growth in melanomas 
(157). In a study on metabolic activity in melanoma subpopulations, it was found that 
blocking mitochondrial respiration and inducing mitochondrial oxidative stress can overcome 
the drug resistance of melanoma cells (143, 158). Chemotherapy, radiotherapy and 
immunotherapy, while not directly intended to disturb the redox state of cells, as well as 
therapy-induced apoptosis and other effects also promote ROS generation (159, 160). 
 
5.4 Mitochondria in melanoma: Liaison between metabolism and signaling 
5.4.1 Mitochondria as the hub of calcium and redox signaling 
Mitochondria have become a focal point in biomedical research field in recent decades due to 
their critical role in both signaling and metabolism. Mitochondrial abnormalities are found to 
be involved in numerous pathologies, including cardiovascular disorders, neurodegenerative 
disorders, diabetes and cancer (161). These findings emphasize the importance of the precise 
regulation of mitochondrial calcium and ROS.  
As the main bioenergetic organelles, mitochondria produce ATP through the OXPHOS of the 
substrate, which is essentially a process of electron transfer via the respiratory electron 
transfer chain complexes to O2. This electron transfer is also coupled to the export of protons, 
which drive ATP synthesis from complex V. However, the electron transfer is not completely 
efficient. Electrons may escape from the transporters and react with nearby O2 which leads to 
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generation of ROS molecules (162, 163). Ca2+ plays an important role in OXPHOS by 
activating key enzymes such as isocitrate dehydrogenase, pyruvate dehydrogenase and 
ketoglutarate dehydrogenase (164, 165). Therefore, Ca2+ is taken up through the 
mitochondrial calcium uniporter (MCU) at the expense of mitochondrial membrane potential 
(166). As a consequence, mitochondrial ATP production and ROS generation are connected 
to mitochondrial calcium uptake; mitochondrial calcium uptake simulates respiratory activity 
and ROS production, but the ROS in turn regulate MCU activity by oxidizing the active 
cysteine residues in the MCU complex and its regulators (167). Such Ca2+-induced ROS 
generation is dependent on respiratory activity. Complexes I and III have been found to be the 
major sources of ROS, and the primary ROS molecules are very often H2O2 and O2- (168-
170). Mitochondrial Ca2+-sensitive K+ has been identified to be another crosstalk pathway for 
Ca2+ and ROS; calcium-induced K+ influx to mitochondrial matrix can lead to alkalinization 
and ROS generation (171). Intrinsically, ROS can also regulate the activity of mitochondrial 
enzymes such as succinate dehydrogenase, ɑ-ketoglutarate to dehydrogenase and aconitase to 
limit the respiration rate, perhaps as a feedback mechanism (172). In addition, Ca2+ also 
induces NO generation, which can inhibit ETC complexes and produce ROS (173, 174). 
Since mitochondrial calcium uptake can buffer the Ca2+ increase in the surrounding cytosol, 
the mitochondria are crucial players in the feedback and shaping of global Ca2+ signals (175, 
176). Hence, the mitochondrial redox status is also influenced by global Ca2+ signaling. The 
mitochondria are very dynamic organelles whose structure, distribution and mobilization can 
be adjusted in response to energy requirements or signaling transduction (177). Thus, in a 
large background, the rearrangement of mitochondria could facilitate crosstalk between 
mitochondrial Ca2+/ROS and inter-organelle communication (178-182).  
The other function of mitochondria is sensing intracellular stress and inducing the apoptosis. 
Mitochondrial calcium overload can trigger the opening of permeability transition pores 
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(PTPs) on the out mitochondrial membrane (OMM) to initiate apoptosis. While the critical 
thiol oxidation of the PTPs serves as another sensing mechanism, the opening of PTPs could 
increase mitochondrial ROS production through the respiratory chain complexes (183, 184). 
Therefore, the inter-dependence between mitochondrial Ca2+ and ROS could be important for 
the regulation of stress-induced apoptosis. 
5.4.2 The mitochondrial function in melanoma 
As mentioned previously, the mitochondria integrate metabolic activities, Ca2+ signaling and 
redox signaling to regulate various aspects of physiological function in both healthy and 
cancerous cells. When it comes to melanoma research, mitochondria are studied in terms of 
the role they play in abnormal metabolic activity and their involvement in those signaling 
pathways that promote aggressive behavior in the hope of developing therapeutic strategies.  
The metabolic shift between glycolysis and respiration depends on the availability of 
substrates and oxygen in normal cells. The shift of metabolic activity towards glycolysis in 
cancer cells under normoxia was termed Warburg effect, which is a hallmark of cancer (185). 
Studies focused on cell viability and intracellular ATP levels have suggested that melanocytes 
are more sensitive to the inhibition of mitochondrial respiration, while, in contrast, melanoma 
cells are more sensitive to the inhibition of glycolysis (186, 187). Further analyses of the 
metabolites of melanocytes and melanoma cells also indicate that glycolysis is more active in 
melanoma cells (188), although mitochondrial respiration occurs even under hypoxia. 
However, in some cell lines or in certain subpopulations of melanoma, mitochondrial 
respiration is upregulated, which suggests the existence of a switching mechanism that allows 
melanoma cells to adapt to the microenvironment (189).  
The heterogeneity of melanoma metabolism is likely caused by the complexity of the driver 
signaling pathways during carcinogenesis and progression, which result in metabolic 
reprogramming to suffice the need for energy of cancer cells (190). The predominant 
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oncogenic mutation in melanoma, BRAF V600E, causes constant activation of the MAPK 
pathway through the BRAF-MEK-ERK axis. It has been reported that the inhibition of BRAF 
also causes downregulation of glycolytic enzymes and glucose transporters (186, 191), which 
correlates with the results obtained from studies on inhibition of ERK activation, suppression 
of downstream transcription factor hypoxia-inducible factor 1α (HIF1α) and v-Myc avian 
myelocytomatosis viral oncogene homolog (MYC) (191). Furthermore, a recent study found 
that the inhibition of BRAF can force melanoma cells to switch to mitochondrial respiration 
and that BRAF suppresses PGC1α via the downregulation of MITF (192, 193). This evidence 
suggests that the BRAF mutation can suppress OXPHOS and enhance glycolysis, both are 
possibly important for the malignant transformation of melanocytes, as the BRAF mutation 
occurs during the early stages of melanoma. However, mitochondrial respiration has been 
reported to be elevated in metastatic melanoma cells (194, 195) and in subpopulations of 
melanoma cells with characteristics such as slow-cycling and/or drug resistant (158, 189). 
Thus, plausible predictions are that elevated glycolysis is the metabolic feature of malignant 
transformation and it supports rapid proliferation in primary melanoma but that high-level 
mitochondrial respiration benefits the progression and survival of melanoma.   
 
5.5 ER-mitochondria contacts in melanoma 
The ER is the largest membrane-bound organelle, and is involved in various cellular functions, 
including protein synthesis and Ca2+ storage. Through electron microscopy, it was discovered 
that ER can form contact sites with organelles including mitochondria, Golgi complexes, 
peroxisomes, endosomes, lysosomes, lipid droplets and plasma membranes (196, 197). 
Among all of these contact sites, the ER-to-mitochondria contact sites are the most important 
and well characterized (198). They are defined as the regions where the membranes of two 
organelles are closely tethered by membrane proteins without any fusion or direct connection 
35 
 
(199, 200). The ER membrane at the contact sites is named the mitochondrial-associated ER 
membrane (MAM), which has been found to be a specialized membrane domain. The tethered 
network has a very dynamic structure that responds to different stimuli (201, 202). The length 
of ER-to-mitochondrial contacts has been measured at 10~30 nM (198). This proximity 
facilitates crosstalk between ER and mitochondrial functions, the majority of which is still not 
fully understood. To date, several main functions of the contact sites have been well 
characterized: inter-organelle lipid exchange; the regulation of mitochondrial biogenesis, 
mitochondrial dynamics and inheritance; coordinating Ca2+ transfer; and mediating stress 
response (203, 204). These functions are intertwined and form an integrated communication 
system between two organelles.  
The role played by the ER-to-mitochondria contact sites and MAM in cancer and in 
melanomas in particular has not been fully investigated, although there is evidence that 
indicates their importance. For example, the MAM can function as a specialized “docking site” 
for signaling molecules to facilitate the regulation of nearby components from critical signal 
pathways. The promyelocytic leukemia protein (PML) located in the MAM could modulate 
the IP3R-Akt signaling pathway to control apoptosis (205) and determine cancer cell fate 
(206). The PTEN can also regulate the Inositol trisphosphate receptor-AKT Serine/Threonine 
Kinase (IP3R-Akt) signaling pathway after being recruited to the MAM. IP3R activation is an 
important event in determining ER Ca2+ release, which, as mentioned previously, initiates the 
SOCE response and ER-to-mitochondria calcium transfer. Thus, these studies imply that the 
ER-to-mitochondria contact sites could be the hotspots for controlling IP3R and Ca2+ 
signaling event, which governs many aspects of melanoma cellular function. Furthermore, the 
upstream activator of Akt, the target of rapamycin complex 2 (mTOR2), has been found to be 
recruited to the MAM by the stimulation of growth factor (207). mTOR is a crucial sensor for 
nutrient availability and metabolism control. Its activation in cancer cells leads to a 
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dependence on mitochondrial bioenergetics (208). Based on these studies, another clue could 
be the ER to mitochondria contact sites are possibly the fundamental structure for the 
“metabolism switching” in melanoma cells.   
Another important role of ER-to-mitochondria contact sites concerns the mediation of stress 
response. ER stress is a complex signaling event triggered by the accumulation of unfolded 
proteins or the dramatic disruption of the ER homeostasis. During the ER stress response, the 
ER morphology changes, and the contact sites are strengthened to adapt to the stress; 
mitochondria have been found to relocate towards the perinuclear ER, perhaps to provide the 
ATP for the response (209). If the stress is severe enough to cause cell death, apoptosis will 
be activated to eliminate the cells. There are studies that have demonstrated that, during this 
phase, the docking proteins can prompt apoptosis by inducing ER-to-mitochondria Ca2+ 
transfer, which leads to mitochondrial calcium overload (210, 211). Melanoma cells are 
extremely resistant to therapies due to the suppression of apoptosis, particularly at advanced 
stages (212, 213). By overexpression of suppressive genes, activating survival pathways or 
inactivation of pro-apoptosis pathways, they acquired the resistance (214). Therefore, some 
drugs that target BRAF-mutated melanoma cells are intended to induce apoptosis via ER 
stress (215) or to exploit the possibility of increasing apoptosis to overcome drug resistance 
(216-218). However, in this context, the influence of contact sites has rarely been investigated, 
thus there still remain many possibilities to investigate in terms of the manipulating of contact 
sites to sensitize melanoma cells for these drugs.   
 
5.6 The TMXs emerged from a genomic-wide screen for NFAT activation 
In 2013, Sonia Sharma et al. published a work on a genome-wide siRNA screen for NFAT1 
activation (219), in which the authors attempted to identify novel regulators of STIM and 
ORAI channels. They used thapsigargin to maximally activate the SOCE in Hela cells and 
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recorded the translocation of GFP-tagged NFAT1 as a readout. Among all the hits, the authors 
identified septins, which reorganize the plasma membrane domains and thus facilitate STIM1-
ORAI1 communication, as novel coordinators of SOCE. It. Notably, a set of thioredoxin-
related transmembrane protein TMX1, TMX3 and Thioredoxin Domain Containing 15 
(TXNDC15) showed relatively high level of inhibition of NFAT1 activation after siRNA-
guided knockdown in Hela cells, which indicates their possible involvement in the cytosolic 
Ca2+ handling.    
5.6.1 Thioredoxin-related transmembrane protein: What is known  
To date, four members of the TMX family have been identified. All of them possess a 
thioredoxin (Trx)-like domain with an active site sequence containing conserved cysteine 
residues, an N-terminal signal peptide and a transmembrane domain; thus, they are 
categorized as members of the thioredoxin (Trx) superfamily. The cellular localization of 
TMX proteins is distinct, but most characterizations have indicated that TMX1 (220), TMX2 
(221), TMX3 (222) and TMX4 (223) are predominantly expressed in the ER, partially on the 
related membrane structures. The first ER residing Trx to be identified was the protein 
disulfide isomerase (PDI), so the TMX proteins are also referred to as the members of the PDI 
family due to their similarity in structure and function. The typical PDI proteins contain four 
domains, a, b, b’ and a’, which are homologous to the cytosolic thioredoxin. The catalytic 
domains a and a’ contain tetrapeptide C-X-X-C active site sequences for disulfide bond 
exchange reactions, while the b domain is responsible for the interaction between enzyme and 
substrate proteins. The catalytic site in PDI is capable of both oxidation and reduction; thus, it 
can oxidize the substrate to reduce the active cysteine residues. In turn, the catalytic site can 
be oxidized by ER oxidase 1 (Ero1), and the electrons are ultimately transferred to molecular 
oxygen, which leads to the generation of H2O2 (224, 225).  
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Functional studies on TMX proteins are relatively scarce, and these proteins’ interaction 
partners and substrate proteins are largely unknown. TMX1 has been identified as a 
transforming growth factor-β-responsive gene in the human adenocarcinoma cell line; when 
expressed in HEK293 cells, it suppresses brefeldin A-induced apoptosis, which leads to the 
conclusion that it may help to relieve ER stress through reversible oxidation of the active site 
(220, 226). Later, it was found that TMX1 is enriched in the MAM (227) and that it controls 
the reprogramming of the metabolism by modulating the ER-mitochondrial Ca2+ flux (228). 
Notably, from the result in the study mentioned above, TMX3 is also partially localized to the 
MAM, which indicates a possible role in regulating MAM homeostasis. However, the early 
study only revealed that TMX3 has an active site motif as C-G-H-C, which might be a 
substrate for Ero1 or an unidentified oxidase, but, intriguingly, during the unfolded protein 
response, TMX3 expression is not upregulated (222). Based on the literature, TMX1 and 
TMX3 share several features of particular interest: First, they share the same active site motif 
involved in disulfide bond formation and may be involved in ER oxidative stress regulation; 
second, they are all localized in the MAM, which is important for mitochondrial function 
modulation; and, third, their involvement in cytosolic Ca2+ has never been reported or studied.  
5.6.2 NFAT signaling in melanoma 
The nuclear factor of activated T cells (NFAT) has been identified in nuclear extracts from 
activated T-cells, which binds to the interleukin-2 promoter (229, 230). It contains a cytosolic 
component which is regulated by phosphorylation via phosphatase calcineurin and nuclear 
GSK3 kinases, a nuclear co-activator activator protein 1 (AP1) and several other partners that 
are regulated by the RAS-MAPK signaling pathways (depicted in Graph 3). Originally, the 
NFAT1 was found to regulate T cell activation and differentiation, but it was later found to 
also be important in dendritic cells, B cells and megakaryocytes. In total, five family members 
have been identified thus far, but only four of them are regulated by cytosolic Ca2+ signaling, 
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which is the canonical pathway that has been extensively investigated and hence used 
frequently for screens. The primordial family member, NFAT5, is only activated by osmotic 
pressure stress. The members of the NFAT family play a crucial role in the development of 
many tissues, including skin (231), and the dysregulations of them are often involved in the 
development of cancer (232). The mutation of NFAT proteins is rare and not associated with 
cancer, but their overexpression and hyperactivity are involved in cancer progression and 
metastasis in lymphoma, breast cancer, prostate cancer, pancreatic cancer, T-cell acute 
lymphoblastic leukaemia (T-ALL), endometrial cancer and melanoma (233). This overview 
of previous studies indicates that the NFAT proteins can influence cell proliferation, 
migration and angiogenesis, as well as the immune response of cancer cells. 
 
Graph 3: The Ca2+-NFAT Signaling Pathway. (Adapted from Martin R. Müller and Anjana 
Rao, Nat Rev Immunol 2010;10:645-656.) 
 
The regulation of NFAT proteins is a very complicated network that includes Ca2+ signaling, 
phosphatases and kinases, various co-activators and an import and export system of the 
nucleus; thus, the mechanisms in the skin and melanomas are varied and not fully understood. 
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It has been suggested that the UV irradiation-induced calcium influx in the skin tissue can 
activate NFAT and contribute to the proliferation of keratinocytes (234, 235), but it also 
causes upregulation of COX-2, which is a proinflammatory, anti-apoptotic and pro-
carcinogenic factor (236). In contrast, further studies have found that Notch 1 and NFAT 
pathways together control the growth and differentiation of keratinocytes and that the loss of 
Notch 1 can lead to lower-level NFAT signaling, which may cause keratinocyte tumor 
development (235, 237). The use of immunosuppressant cyclosporine A (CsA), which inhibits 
the phosphorylation of NFAT by calcineurin for organ transplants in patients, has been found 
to increase the risk of cancers by suppression of the immune system. (238).  
The studies conducted over the past decade have indicated that NFAT signaling is involved in 
the proliferation, metastasis and apoptosis resistance of melanoma. Flockhart and colleagues 
found that, in metastatic melanomas, oncogenic BRAF V600E can activate NFAT2 and 
NFAT4, which leads to the expression of COX-2 and a poor prognosis (239). This work 
provided the first evidence that the NFAT signaling pathway is involved in major mutation 
events; however, this conclusion was based on a comparison between primary melanocytes 
and three BRAF mutation-positive cell lines, which meant that other melanoma cases were 
not considered. A later study found that permanently activated NFAT2 inhibits apoptosis in 
melanoma (240). More recent studies have found that NFAT1 promotes tumor growth and 
metastasis by increasing interleukin-8 and MMP3 expression; in addition, the expression of 
NFAT1 has been found to be inversely correlated with MITF expression in melanomas, which 
suggests that NFAT1 can promote melanoma dedifferentiation and immune escape (241, 242). 
Notably, as an alternative co-activator of NFAT proteins, FOXP3 expression is also related to 
the proliferation, apoptosis and modifying of the tumor environment in melanomas, which 
might be attributed to the NFAT pathway; however, due to the different models used in these 
studies, a more comprehensive overview is required (243-245). Finally, the inhibitor of 
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calcineurin CsA can also inhibit proliferation and induce apoptosis in melanoma cells (246, 
247), but, due to the complexity of the signaling pathways in which calcineurin is involved, it 
is not clear if NFAT proteins are also responsible in this case.  
 
5.7 Research focus and questions for the investigation 
As mentioned previously, the mitochondria are dynamic organelles that integrate Ca2+ 
signaling, redox regulation and bioenergetics to control important functions such as 
proliferation, migration and apoptosis in both normal and cancerous cells. As the 
communicative junction, the ER-mitochondria contact site is crucial for the integrated signal 
transduction, but a comprehensive understanding of the underlying mechanism in the context 
of melanoma pathogenesis and therapeutics is required. Previous studies on TMX1 and 
TMX3 have indicated their localization in the contact site and roles in controlling of cell 
metabolism in melanoma; however, the single cell-based model leaves many questions 
unanswered. Furthermore, TMX1 and TMX3 have been found to be the regulators of the 
NFAT1 signaling pathway, which plays important roles in many aspects of melanomas, but 




6 Materials and Methods 
6.1 Materials 
6.1.1 Chemicals 
The chemicals, fluorescent dyes and other reagents used for this study are listed below. The 
chemicals for general use in the laboratory were purchased from Sigma-Aldrich (Darmstadt, 
Germany) if not included in the list. 
Table 1: Chemicals 
Chemical Supplier Catalog-/Order-
Number 
2-Mercaptoethanol Sigma M6250 
Antimycin A Sigma A8674 
Acrylamide-Bisacrylamide Sigma A2792 
Accutase Sigma A6964 
Agarose  Sigma A9539 
Bovine Serum Albumin Sigma A2153 
Ammonium chloride (NH4Cl) Sigma A9434 
Ammonium persulfate Sigma A3678 
1,2-Bis(2-Aminophenoxy)ethane-
N,N,N′,N′-tetraacetic acid (BAPTA) 
Sigma A4926 
Calcium chloride solution (CaCl2) Sigma 21115 
CellMask™ Green  ThermoFisher  C37608 
Chloroform (99 %) Sigma C2432 
Protease Inhibitor Cocktail Roche 05892970001 
Diethylpyrocarbonate (DEPC) Sigma D5758 
Dimethylsulfoxide (DMSO) Sigma D2650 
DTT Sigma D9779 
Ethanol Sigma 48075 
Ethylenediaminetetraacetic acid  Sigma E9884 
EGTA Sigma E4378 
FCCP Sigma C2920 
Fetal bovine serum Invitrogen/Gibco 10500064 
Fura-2 AM Invitrogen F1221 
FuGENE® HD Promega E2312 
GKT137831 Cayman Chemical 17764 
Glucose Merck 108337 
Glycine Applichem A1067 
Glycogen Sigma G1767 
H2O2 (10M) Sigma H1009 
HEPES  Sigma H7523 
Insulin solution (human) Sigma I9278 
Ionomycin Sigma I9657 
Isopropanol Sigma W292907 
M2 medium Sigma M7167 
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Magnesium chloride solution (MgCl2) Sigma M1028 
Methanol Sigma 322415 
MitoTracker™ Deep Red FM ThermoFisher  M22426 
MitoTEMPO Biomol Cay16621 




NP-40 Sigma 73485 
Oligomycin A Sigma 75351 
PEG-catalase Sigma C4963 
Poly-L-ornithine hydrobromide Sigma P3655 
Potassium bicarbonate (KHCO3) Sigma 12602 
Potassium chloride (KCl) Sigma P9333 
Puromycin VWR 540222-25 
Rotenone Sigma R8875 
Sodium chloride (NaCl) Sigma S7653 
Sodium dodecyl sulphate (SDS) Sigma L3771 
Streptavidin Peroxidase Calbiochem 189733 
Thapsigargin (Tg) Invitrogen™ T7458 
Trizma® hydrochloride Sigma T5941 
Trizma® base Sigma T1503 
Triton™ X-100 Sigma X100 
TRIzol® Reagent Invitrogen™ 15596026 
TWEEN® 20 Sigma 93773 
 
6.1.2 Solutions and Culture Media 
The solutions, buffers and media in the following list were used for assays or cell culture 
according to the manufacturer’s instructions.  
Table 2: Solutions and Culture Media 
Item Supplier Catalog-/Order-
Number 
Dulbecco’s Phosphate Buffered 
Saline (DPBS) 
Invitrogen/Gibco 14190094 
L15 Leibovitz liquid medium Merck/Biochrom F 1315 
MCDB 153 basal medium Merck/Biochrom F 8105 
RPMI 1640 L-Glutamine+ Medium Invitrogen/Gibco 21875-034 
MEM-Medium + L-Glutamine Invitrogen/Gibco 31095-029 
Dulbecco's Modified Eagle Medium Invitrogen/Gibco 11965-084 
Opti-MEM™ Invitrogen/Gibco 31985070 




6.1.3 Solutions and buffer recipes 
The recipes for the home-made solutions are provided below. Unless indicated otherwise, 
these standard recipes were used for all experiments including calcium imaging and live-cell 
imaging. 
Table 3: Recipes for home-made solutions 
Solution Composition 
Ringer’s solution (0mM Ca2+) NaCl 145mM 
KCl   4mM 
Glucose 10mM 
MgCl2 2mM 
HEPES pH 7.4 10mM 
EGTA 1mM 
Ringer’s solution (0.25mM Ca2+) NaCl 145mM 
KCl   4mM 
Glucose 10mM 
MgCl2 2mM 
HEPES pH 7.4 10mM 
EGTA 1mM 
CaCl2 0.25mM  
Ringer’s solution (0.5mM Ca2+) NaCl 145mM 
KCl   4mM 
Glucose 10mM 
MgCl2 2mM 
HEPES pH 7.4 10mM 
EGTA 1mM 
CaCl2 0.5mM 
Ringer’s solution (1mM Ca2+) NaCl 145mM 
KCl   4mM 
Glucose 10mM 
MgCl2 2mM 
HEPES pH 7.4 10mM 
EGTA 1mM 
CaCl2 1mM 
Ringer’s solution (2mM Ca2+) NaCl 145mM 
KCl   4mM 
Glucose 10mM 
MgCl2 2mM 
HEPES pH 7.4 10mM 
EGTA 1mM 
CaCl2 2mM 
Ringer’s solution (10mM Ca2+) NaCl 145mM 
KCl   4mM 
Glucose 10mM 
MgCl2 2mM 





2% TU medium  
 
MCDB153 (80% of total volume) 
Leibovitz-15 Medium (20% of total volume) 
2% FCS 
1,68mM CaCl2 (1,68mM) 
2.5ng/ml Insulin 
TGH lysis buffer (100mL) 1% Triton X-100 (10mL of 10% stock) 
10% Glycerol (20mL of 50% stock) 
5M NaCL 1ml 50mM 
1M HEPES 5ml 50mM 
200mM EGTA 0.5ml 1mM 




6.1.4 Primers for PCR 
The primers used for qPCR experiments are listed below (From 5’ to 3’). 
Table 4: Primers for PCR 
Transcript Forward Reverse 
TMX1 AGTCCTGGTGCTGTTGCTTT TTCTCCCCATTCAGCAAAAC 
TMX3 TTGCTATGGATGGCTTCCTC TGGGACTGTCAATTCATCCA 
NFAT1 AAACTCGGCTCCAGAATCCA TGGACTCTGGGATGTGAACT 
NFAT2 GCTATGCATCCTCCAACGTC AGTTGGACTCGTAGGAGGAG 
NFAT3 ACACAGCCCTATCTTCAGGA ATCTTGCCTGTGATACGGTG 
NFAT4 ACCCTTTACCTGGAGCAAAC CTTGCAGTAGCGACTGTCTT 
NFAT5 CGTGTGTGTGGCTTCTATGT TGCCTCTCAATCAGAGAGAG 
XBP1 CACCTGAGCCCCGAGGAG TTAGTTCATTAATGGCTTCCAGC 
TBP CGGAGAGTTCTGGGATTGT GGTTCGTGGCTCTCTTATC 
 
6.1.5 siRNA and shRNA 
The siRNA and shRNA were used for the knockdown of target gene expression, the 
sequences are provided in Table 5. The scrambled control siRNA was purchased from the 
same supplier accordingly. For shRNA experiments, the pLKO.1 empty vector was used as 
the control. The design, synthesis, sequencing and quality check were all done by the 
manufacturers.  
Table 5: siRNA and shRNA 
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Item Sequence Supplier Catalog
/Order 
Number 
siTMX1 5’-GAGAAGAUCUUGAGGUUA A dTdT-3’ MicroSynth 481616 
siTMX3 5’-GGAGUUCGAGGUUAUCCAA dTdT-3’ MicroSynth 2920934 
















    
 
6.1.6 Primary Antibodies 
The primary antibodies used for western blot analyses and immunohistochemistry are listed 
below. 
Table 6: Primary Antibodies 
Target Supplier Catalog-/Order-Number 
TMX1 Abcam Ab37876 
TMX3 Provided by Prof. Lars Ellgaard 
(Copenhagen, Denmark) 
/ 
GAPDH Cell Signaling Technology #2118L 
BiP and PDI Provided by Prof. Dr. Richard 
Zimmermann (Homburg, Germany) 
/ 
NFAT1 Cell Signaling Technology #5861S 
 
6.1.7 Assay kits 
Commercially available kits were used for specific assays and procedure. Any supplementary 
components were made following manufacturer’s recommendations. 
Table 7: Commercially Available Kits  
Item Supplier Catalog-/Order-
Number 





Amaxa P2 Primary Cell 4D-Nucleofector® LONZA V4XP-2024 
Amaxa SF Cell Line 4D-Nucleofector® LONZA V4XC-2024 
Calcineurin cellular activity assay kit ENZO BML-AK816-0001 
CellTiter-Blue® Promega G8081 
Complete Proteinase-Inhibitor cocktail Roche 05892791001 
HTS Transwell®-24 well permeable support Corning® 3422 
HTS Transwell®-96 well permeable support Corning® 3374 
Human IL-8/CXCL8 DuoSet ELISA R&D systems DY208 
HiSpeed Plasmid Maxi Kit Qiagen 12662 
Pierce™ BCA Protein Assay Kit ThermoFisher 23225 
QuantiTect SYBR Green kit Qiagen 204145 
Superscript II Reverse Transkriptase Kit Invitrogen 18064-014 
 
6.1.8 Peripherals 
The peripheral items used for the experiments are listed below. 
Table 8: Peripheral materials 
Item Supplier Catalog-/Order-
number 
Baysilon-Paste high viscosity GE Bayer Silicones 700514 
Coverslip (25mm) ORSATec / Kindler 02R1215-D 
Immersol 518F fluoresence free, 23° C Zeiss 444960-0000-000 
Immersol 518F fluorescence free, 37° C Zeiss 44970-9010-000 
nitrocellulose membrane GE Healthcare 10600003 
 
6.1.9 Devices 
The devices used in the experiments are listed below; small devices for general laboratory use 
are not listed. 
Table 9: Devices  
Item Supplier Function 
4D-Nucleofector™ System LONZA Transfection of siRNA 
Nucleofector™ 2b Device LONZA Transfection of siRNA 
Centrifuge 5415C Eppendorf Centrifugation 
Infinite M200 Pro Tecan Plate reader 
Nucleic Acid Electrophoresis Systems BIO RAD Electrophoresis 
Cell Observer Z1 Zeiss Live cell imaging 
Evolve® 512 EMCCD Camera PHOTOMETRICS Live cell imaging 
Olympus IX70 Olympus Calcium imaging 
Polychrom V Till Photonics Calcium imaging 
CCD Camera Imago Till Photonics Calcium imaging 
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CLARIOstar® BMG LABTECH Plate reader 
BioPhotometer Eppendorf Spectrophotometer 
 
6.1.10 Microscopes 
6.1.10.1 Zeiss Cell Observer Z1 
The live cell imaging experiments performed for the current study were either done on an 
automatic Zeiss cell observer Z1 or a similar semi-automatic Zeiss cell observer D1 system 
including a Colibri LED light source, an incubation chamber with gas and temperature control 
units, fast acquisition cameras and a special trigger unit (used to achieve high frame rate 
imaging). The setup is as shown in the photo below. 
 
Graph 4: Zeiss Cell Observer Z1 imaging setup. A: Computer B: Cell Observer Z1 C: 
Evolve®512 Delta EMCCD Camera D: Atmosphere control E: Temperature control F: Power 
supply unit 
 
6.1.10.1.1 LED sets 
The LEDs are installed in a Colibri system. They provide light sources with fixed wavelength 
for the excitation of different fluorescent proteins or dyes. The excitation wavelengths of LED 
sets and beam combiners are listed below.  
Table 10: LED Sets on the Zeiss Colibri 2 System  
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LED (wavelength) Beam Combiner 
400nM Beam Combiner 425nm+Beam Combiner 490nm 
420nM Beam Combiner 425nm+Beam Combiner 490nm 
490nM Beam Combiner 565nm+Beam Combiner 490nm 
505nM Beam Combiner 565nm+Beam Combiner 490nm 
555nM Beam Combiner 565nm+Beam Combiner 490nm 
 
6.1.10.1.2 Emission Filters and Dichroic Mirror Sets 
The emission signals from the fluorescent proteins passed through a dichroic system and are 
filtered by the emission filter sets before being detected by the sensor of camera. The filter 
and dichroic mirror system are built on an automatic or semi-automatic revolver which can be 
controlled by a computer. The emission filter and matched dichroic mirrors are listed below.  
Table 11: Emission Filters and Dichroic Mirror Sets  
Dichroic Mirror Emission Filter 
FT 509nm 528nm/40 
FT 505nm 525nm/50 
FT 520nm  542nm/27 
BS 458nm 483nm/32 
FT 573nm 630nm/92 
 
6.1.10.1.3 Objectives 
Different objectives were used to visualize cellular signals. These objectives are listed below. 
Table 12: Objectives on the Zeiss Cell Observer  
Manufacturer Type Magnification Numerical 
Aperture 
Serial number 
Zeiss Fluar  2.5× 0.12 420120-9900 
Zeiss Fluar 10× 0.5 420140-9900 
Zeiss Fluar 20× 0.75 420150-9900 
Zeiss Fluar 40× 1.3 420260-9900 
Zeiss Fluar 100× 1.45 421190-9900 





To achieve proper time resolution for live cell imaging, fast acquisition cameras were used for 
the experiments. The specifications of cameras are listed below. 
Table 13: Cameras for Live Cell Imaging  
Manufacturer Type Sensor Array Size Pixel Size 
Zeiss Axiocam 702 mono IMX174 Exmor 
Pregius 
1928×1200 5.86× µm 
Photometrics® Evolve® 512 Delta E2V CCD97 512×512 162 µm 
 
6.1.10.2 Olympus IX70 Setup 
The Olypmus IX70 imaging setup was used for the ratiometric calcium imaging experiments; 
the components of full system are listed below. 
Table 14: Olympus IX70 Components 
Components Function 
Olympus IX70 microscope Imaging 
Computer Data processing 
Polychrome V Monochromator Excitation light source 
CCD-Camera T.I.L.L. Imago Recording 
20× Objective Visualization 
Filter sets Customized for Fura-2 spectrum 
 
6.1.11 Cell Lines 
All melanoma cell lines labeled with “WM” and “Lu” are a gift from Prof. Dr. Meenhard 
Herlyn (The Wistar Institute, Philadelphia, USA); additional melanoma cell lines were 
purchased from German Collection of Microorganisms and Cell Cultures GmbH and 
American Type Culture Collection. The primary human melanocytes were a gift from Dr. 
Hedwig Stanisz-Bogeski (Dermatology, Göttingen).  
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Experiments on human cell lines or primary cells were approved by the local ethics 
committees. Culture medium, the origin and genetic information of all used cell lines are 
provided below.  
Table 15: Panel of Cell Lines Used for the Current Study 
Cell line BRAF N-RAS PTEN Culture Medium 
WM3734 V600E WT WT TU+2% FCS 
Mel Juso WT Q61K WT RPMI 1640+10% FCS 
WM164 V600E WT WT TU+2% FCS 
WM983B V600E WT WT TU+2% FCS 
1205Lu  V600E WT Hem Del TU+2% FCS 
WM9 V600E WT Hem Del TU+2% FCS 
WM3918 WT WT N/A TU+2% FCS 
SK Mel 5 V600E WT WT RPMI 1640+10% FCS 
451Lu C2 V600E WT WT TU+2% FCS 
WM1366 WT Q61L WT TU+2% FCS 
HaCat WT WT WT DMEM+10% FCS 
Melanocyte WT WT WT M2 medium+1% Pen/Strep 
HeLa - - - DMEM+10% FCS+1% Pen/Strep 
 
*Sequencing analyses of the Wistar melanoma cell lines were performed in the K. Nathanson 
laboratory, University of Pennsylvania, Philadelphia, USA. All melanoma cell lines have been 
fingerprinted for their uniqueness to exclude cross-contamination. (WT, wild type; Hem Del, 
hemizygous deletion). The mycoplasma contaminant tests were done with a commercially 
available kit.   
 
6.1.12 Genetically Encoded Protein Sensors 
Genetically encoded protein sensors are used for monitoring of cell signaling and activities of 
specific molecules in a quantitative and real-time manner in different intracellular 
compartments. Compared with broadly used fluorescent dyes, the protein sensors offer the 
opportunities for more precise monitor of the cellular physiological activities. In the current 
study, the protein sensors were applied to measure calcium, ROS and ATP concentration in 
compartments including cytosol, ER and mitochondria. The information for the labeled 
reporters and protein sensors is provided below. 
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Table 16: Genetically Encoded Protein Sensors 
Item Feature Targeted Compartment Function 
NFAT1-GFP  GFP reporter Cytosol NFAT1 activation 
HyPer3 Ratiometric Cytosol H2O2 concentration 
Mito HyPer Ratiometric Mitochondria H2O2 concentration 
SypHer Ratiometric Cytosol pH  
Mito SypHer Ratiometric Mitochondria pH 
4mt D3cpV FRET Mitochondria Ca2+ concentration 









CaNAR2 cyto FRET Cytosol Calcineurin activity 
 
6.2 Methods 
6.2.1 Cell culture 
All cell lines used in this study were cultured with corresponding media supplemented with 
fetal bovine serum and were maintained in a standard incubator with a temperature control at 
37°C, supplied with 5% CO2. Specific culture conditions for the major cell lines used in this 
study are as follows. 
WM3734 
The WM3734 cell line was established on site at the Wistar Institute, Philadelphia, PA USA 
(M. Herlyn Laboratory) as previously published (248). The cells were isolated from a brain 
metastasis of human melanoma in a female patient. The cells were maintained in 2% TU 
medium and split twice a week. 
Mel Juso 
The Mel Juso cells originate from a human primary melanoma tumor, purchased from 
German Collection of Microorganisms and Cell Cultures GmbH. The cells were cultured in 




Human melanocytes were used for comparisons to the melanoma cells in expression analysis. 
The melanocytes were isolated from neonatal foreskins obtained after circumcision from 
different donors and were cultured according to established protocols.  
*The melanocytes were provided by Dr. Hedwig Stanisz-Bogeski (Dermatology, 
Universitätsmedizin Göttingen, Göttingen).  
 
6.2.2 RT-PCR 
6.2.2.1 RNA isolation 
The TRIzolTM reagent from Invitrogen was used to isolate total RNA from the cells and tissue 
sample in the present study. Briefly, cells were detached by incubation with accutase, they 
were centrifuged at 1500 rpm for 3 minutes. The pellet was then suspended by pipetting the 
TRIzolTM reagent. The samples were then stored at -20°C if not used immediately. The 
isolation proceeded by the sequential precipitation of total RNA using different solutions, 
following manufacturer’s instructions. The yield of isolated total RNA was measured by 
reading the absorbance with a spectrophotometer; the RNA concentration was calculated 
using the formula: A260 (absorbance at 260nm) ×dilution×40 = μg RNA/mL. 
6.2.2.2 Reverse transcription 
Generally, 800 ng of total isolated RNA was reverse-transcribed to cDNA using 
SuperScriptTM II reverse transcriptase following manufacturer’s instruction; the link of the 
instruction is as follows:  
https://assets.thermofisher.com/TFS-Assets/LSG/manuals/superscriptII_pps.pdf. 
6.2.2.3 RT-qPCR 
A volume of 0.5 µL cDNA was used for q-PCR experiment using the SYBR Green Kit 
(Qiagen #204145) and Bio-Rad CFX96™ Real-Time System. The TATA box binding protein 
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(TBP) was set as the housekeeping gene. Analyses were performed using the 2-CT method. 
The qPCR experiments in the current study were run on either the Biorad® Light Cycler or 
Agilent technologies® stratagene mx3000p*. 
*The transfection, treatment of cells, sample collection and data analysis were performed by 
Xin Zhang, the RT-PCR experiments were performed by the laboratory technicians Andrea 
Paluschkiwitz (Universitätsmedizin Göttingen, Göttingen) and Sandra Janku (University of 
Saarland, Homburg-Saar). 
 
6.2.3 Western blotting 
To analyze the knockdown efficiency of the siRNA/shRNA or the expression of target 
proteins across a panel of melanoma cell lines and melanocytes, the western blot analyses 
were applied. The general experimental procedure is described below. 
Generally, 2×106 cells were harvested using accutase or trypsin, the cell pellets were stored at 
-80°C before use. The tumor samples from mouse xenografts were fixed and embedded in 
paraffin, or frozen instantly on site using liquid nitrogen. The determination of the protein 
concentration was performed using the Bradford or BCA protein assay, 25µg protein were 
loaded on 10% SDS-polyacrylamide gel for the electrophoresis. After the electrophoresis, the 
samples were transferred onto a nitrocellulose membrane and blocked in 5% BSA. The blots 
were incubated with specific primary antibodies overnight and then incubated with 
fluorescent secondary antibodies in dark, at room temperature for hours. The blots were 
scanned with a BioRad imaging system.   
*The transfection, treatment of cells and tumor sample collection were performed by Xin 




6.2.4 RNA oligonucleotide mediated gene silencing 
To study the physiological function of the TMX proteins and NFAT1, the RNA interference 
technique was used to knockdown the expression of the target proteins.  
For the transient knockdown, the small interference RNA (siRNA) was introduced by 
electroporation-mediated transfection with a 2b or 4D Nucleofector machine from LONZA. 
The cells were suspended with a mixture of siRNA and salt free solution provided by the 
supplier, and were electroporated with optimized programs.  
Briefly, two million cells were harvested by trypsinization and centrifuged at 1000 RPM for 3 
min; the supernatants were discarded. The cells were suspended with 4µL of 20pmol siRNA 
in 100µL transfection solution and were loaded into cuvettes. Pre-optimized programs were 
used for the electroporation according to cell types. The programs defined the type, number 
and voltage of the electroporation to be executed. After the electroporation, cells were 
immediately transferred into pre-warmed growth medium, they were seeded and kept in the 
incubator until measurement started. The programs used for electroporation are listed as 
follows.  
Table 17: Programs Used for the Transfection by Electroporation  
System Program Cell Line 
4D-Nucleofector™ System CA137 WM3734 
Nucleofector™ 2b Device A24 WM3734 
Nucleofector™ 2b Device A24 Mel Juso 
 
For the stable knockdown of TMX1, the Sigma MISSION® shRNA was transduced into 
WM3734 and 1205Lu melanoma cells with a lentiviral vector pLKO.1, the control cells were 
transduced only with scrambled pLKO.1 vector. All procedures followed the RNAi 




The workflow for the generation of stable TMX1 and TMX3 knockdown cell lines was as 
follows: 
Day 1: Seed 4 million recently thawed HEK293T cells in 10ml antibiotic-free medium in 
10cm tissue culture dishes for packaging.  
Day 2: Transfect the HEK293T cells with lentivirus plasmids of control, shRNA against 
TMX1 and TMX3 by lipofection. The composition of the mixture for transfection is as 
follows: 1) Packaging plasmid psPAX2 9µg; 2) Envelope plasmid PMD2.G 0.9µg; 3) empty 
vectors pLKO.1 or shRNA 9µg; 4) Opti-MEM to a total volume 225µL. The transfection 
reagent mixture is as follows: 1) lipofectamine 54µL; Opti-MEM 90µL. 
Day 3: 18 hours after transfection, remove the medium and add fresh high-serum medium. 
Day 4: 24 hours later, collect the medium with virus and add fresh medium.   
Day 5: 24 hours after first collection, collect the medium with virus and discard packing cells. 
The virus was stored in -80°C before use.  
Day 6: Seed the target cells at 50%~60% confluence. 
Day 7: Infection of cell lines with virus and 8µg/mL polybrene in complete medium, and 
incubate for 16 hours.  
Day 8: Discard supernatant from dish and wash 3 times with PBS, then add fresh medium.  
Day 9: After 24 hours, discard the supernatant and replace with medium plus 2µg/mL 
puromycin. Wait for the selection for 72 hours.  
Day 12: Refresh the medium and wait for the recovery of cells. 
*The establishment of TMX1 and TMX3 stable knockdown cell lines were performed by Xin 
Zhang, and the cell lines were shared to collaborators for subsequent experiments including 
57 
 
western blot analysis of cell signaling pathways, Matrigel invasion assay, mitochondrial 
respiration capacity analysis, electron microscopy analysis, determination of mitochondrial 
volume and surface by confocal microscopy, mouse model based work.  
 
6.2.5 NFAT1 translocation assay 
To monitor the activation of transcription factor NFAT1, a microscopy-based NFAT1 
translocation assay was performed using GFP tagged NFAT1. Melanoma cells were seeded 
onto glass coverslips at a density of 200,000 cells per well (6-well plate) and left for adhesion 
overnight. The next day, the cells were transfected with a NFAT1-GFP construct using 
FuGENE® HD solution, 1µg plasmid plus 4µL FuGENE solution and 100µL Opti-MEM for 
each well in 2ml growth medium. Six hours later, the medium was refreshed. Twenty-four 
hours after the transfection, the cells were loaded in 0.25mM Ca2+ or 1mM Ca2+ Ringer’s 
buffer and were stimulated with thapsigargin (1µM). The translocation of NFAT1 was then 
recorded by live cell imaging at 37°C. The increase in fluorescence intensity in the nucleus 
was calculated by an Axiovision software using marked regions of interest, and the results 
were normalized by calculating the ratio of Fn/F0 fluorescence intensity (ratio of fluorescence 
signal intensity number from frame N divided by the fluorescence signal intensity number 
from the first frame) 
 
6.2.6 Cell viability assay 
To analyze the viability of melanoma cells, the CellTiter-Blue® Cell Viability Assay was used 
following the manufacturer’s protocol. The assay is developed on the conversion of resazurin 
into its fluorescent form by viable cells. Since nonviable cells or metabolically interfered cells 
lose the capacity to reduce the resazurin, emitted fluorescence signals can be used as a 
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reference of cell viability. Thus the assay provides a simple and reliable method to measure 
the viability of the cells. The details of the procedure are as follows.  
The collected cells were suspended in full medium, and 10µL of the suspension was loaded 
into a counting cassette. The cell number was determined either with a Moxi™ Z Mini 
Automated Cell Counter or a Life Technologies® Countess II FL Cell Counter. The cells 
were seeded at a density of 5,000 cells/well (96-well palte), or 10,000 cells/well (48-well plate) 
in 200µL or 400 µL growth medium respectively. Generally, 6 hours after the seeding, the 
cells were treated with activators/inhibitors for the specified time duration. After the treatment 
or the incubation time, 20µL (96-well plate) or 40µL (48-well plate) CellTiter-Blue were 
added per well and incubated with the cells for 3 hours. After the incubation, the plates were 
shaken for 20 seconds and the fluorescence signals emitted at the wavelength of 590nm (but 
excited at a wavelength of 560nm) were measured by a TECAN M200 plate-reader. The 
background signal from the wells filled only with medium and CellTiter-blue was subtracted 
from the measured wells, and the fluorescence intensity in arbitrary units was used to 
determine cell viability.  
 
6.2.7 Cell migration assay  
The migration assay was performed using a HTS transwell® permeable support (Corning®, 
Kennebunk ME, USA) with 8-um pore size inserts. Cells were seeded at 50,000cells per well 
(96-well plate) or 100,000 per well (24-well plate) in FBS-free medium containing 50ng/mL 
Wnt5a recombinant protein and were made to migrate towards a lower compartment 
containing preconditioned medium supplemented with 10% FBS. After 48 h, cells that 
migrated across the membrane were detached by digestion with accutase and suspended in 
PBS with 5% FCS, then counted using a Moxi Z Mini cell counter (ORFLO technologies, 
Ketchum, USA) or Life Technologies® Countess II FL Cell Counter. 
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6.2.8 Calcium measurement 
6.2.8.1 Fura-2 AM based cellular calcium measurement 
Measurements with the ratiometric calcium binding dye Fura-2 AM were performed for the 
quantification of cellular calcium concentrations. Melanoma cells were seeded at a density of 
200,000 cells per well onto coverslips in 6-well plates and were incubated overnight for 
adhesion. The cells were stained with 1µM Fura-2 AM in growth medium for 30 min at room 
temperature in the dark. The measurements were performed in Ringer’s buffer (pH 7.4) 
containing 155mM NaCl, 2mM MgCl2, 10mM glucose, 5mM HEPES and different 
concentrations of CaCl2 or 0mM CaCl2 plus 1mM EGTA and 3mM MgCl2. The cells were 
loaded with calcium free Ringer’s buffer for the measurement of basal calcium levels, then 
the cells were perfused with 1µM of the SERCA (sarco/endoplasmic reticulum Ca2+-ATPase) 
inhibitor thapsigargin (Tg) which triggers a strong and irreversible depletion of ER Ca2+, 
leading the activation of SOCE. After the intracellular calcium level returned to resting level, 
the extracellular calcium concentration was increased by perfusion of the cells with Ringer’s 
buffer containing 0.25mM or 1mM Ca2+ to record the Ca2+ influx through the plasma 
membrane channels. Time-lapse ratio-metric images were recorded with an Olympus IX70 
microscope at a pace of one frame per 5 seconds. The results were analyzed with the 
TILLVISION software (FEI Munich, GmbH). 
6.2.8.2 Compartmental calcium measurement 
To measure the calcium dynamics in different cell compartments, the genetically encoded 
protein sensors were introduced into the cells by transfection using FuGENE® HD solution. 
Generally, the plasmids were transfected 24 hours before the imaging experiment. The live 
cell imaging experiments were performed on the Zeiss Cell Observer using Zeiss Axiovision 
or ZEN software. The measurements were performed using Ringer’s buffer (pH 7.4) 
containing 155mM NaCl, 2mM MgCl2, 10mM glucose, 5mM HEPES and different 
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concentrations of Ca2+. Thapsigargin was used for depleting the ER store, and the 
extracellular calcium concentration was altered by perfusion or adding Ringer’s buffer with 
various Ca2+ concentrations. The results were analyzed with the Zeiss software. For different 
sensors, the formulas described below were used for the calculation of the ratio representing 
the relative calcium concentration.  
FRET donor Ratio= [(fretgv-bgfret) - cfdon*(dongv-bgdon) - cfacc*(accgv-bgacc)]/ (Donorgv-bgdonor) 
Ratio Fn to F0= (Intensityn-bgn)/ (Intensity0-bg0) 
Ratio CH1 to CH2= (Channel1-Channelbg)/ (Channel2-Channelbg) 
(*Regarding the subscripts in formula: gv=given; bg=background; don=donor; acc= 
acceptor; n= frame n; 0= frame 0; CH1=channel 1; CH2=channel 2; CF=correction factor.) 
 
6.2.9  Intracellular H2O2 measurement 
The concentration of H2O2 in different cellular compartments such as ER and mitochondria 
were measured using the protein sensor HyPer3, ER HyPer and mito-HyPer respectively. The 
protein sensors were introduced into cells by transfection using FuGENE® HD solution as 
described before. The live cell imaging was performed on the Zeiss Cell Observer. The LEDs 
with excitation wavelengths of 420nm and 505nm were used and the emission signals were 
collected through the YFP filter with a passing wavelength of 542nm±14. The cells were 
loaded with the Ringer’s buffer (pH 7.4) containing 155mM NaCl, 2mM MgCl2, 10mM 
glucose, 5mM HEPES and 0.25mM CaCl2, and were pre-incubated for 5min before imaging. 
On average, at least 3 different fields were recorded for each coverslip. To measure the signal 
of the fully reduced HyPer probes and subtract it as the background signal, cells were 
incubated with 100µM N-acetylcysteine (NAC), 1mM DTT or 100nM Mito TEMPO for 
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25min. Results were analyzed using Zeiss Axiovision or ZEN software and are presented as 
ratio values of the emission or the relative percentage numbers of the control group. 
 
6.2.10 Intracellular pH measurement 
To monitor the pH of the cellular compartments as a control for the HyPer probes, the pH 
sensitive mutant SypHer probes were used for experiments in parallel. The transfection and 
measurement of the SypHer probes were done following the same procedure as with HyPer 
probes mentioned above. The results were analyzed with the same software accordingly and 
presented as the ratio of emissions from excitation wavelengths of 505nm and 420nm.  
 
6.2.11 Mitochondrial ATP concentration measurement 
The mitochondria targeted FRET protein sensor ATeam1.03 was used to measure the basal 
mitochondrial ATP concentration. Briefly, cells were seeded on the glass coverslips following 
the same procedure for imaging experiments. The ATeam1.03 plasmid was transfected using 
FuGENE® HD solution 24 hours prior to the measurements. Cells were loaded with Ringer’s 
buffer containing 0.25mM Ca2+ and were imaged at 37 °C with the excitation wavelengths of 
420nm and 505nm; and emission wavelengths of 483±16 nm and 542±14 nm. To measure the 
minimum level of ATP and subtract the signal from the ATP generated from other sources 
than mitochondrial respiration, 4µM oligomycin was used to fully block the ATP generation 
from the ATP synthase. Results were analyzed with Axiovision software and are presented as 
FRET donor ratio.  
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6.2.12 Calcineurin activity assays 
6.2.12.1 Dynamic measurement of calcineurin activity 
The dynamic phosphorylation activity of cytosolic calcineurin upon activation by calcium 
entry was measured with the FRET protein sensor CaNAR2-cyto. Melanoma cells were 
seeded onto glass coverslips and were incubated 4 to 6 hours for adhesion. The plasmid was 
transfected using FuGENE® HD solution 48 hours prior to the measurements. Cells were 
loaded with Ca2+ free Ringer’s buffer at the beginning of measurements, the Ca2+ influx and 
subsequent activation of calcineurin was induced by adding 1µM thapsigargin, 1µM 
ionomycin and Ringer’s buffer containing 2mM Ca2+ to elevate the final extracellular Ca2+ 
concentration to 1mM. The FRET signal was collected through an emission filter with a 
wavelength of 542±14nm. The FRET/CFP ratio was calculated using the Axiovision software 
and is presented as the relative phosphatase activity of calcineurin. 
6.2.12.2 Enzymatic end point measurement of calcineurin activity 
A commercially available kit for cellular calcineurin activity (BML-AK816-0001, Enzo Life 
Sciences, USA) was purchased and used for the end point measurement of calcineurin 
phosphatase activity in melanoma cells. Melanoma cells were transfected with the siRNA, 
and 2x106 cells were seeded in a T25 cell culture flask. By 48 h, the cells were washed with 
cold TBS for 3 times and were incubated with 0.5mL accutase for detachment. The cells were 
suspended, and the cell number in suspension was determined with a Moxi mini cell counter. 
Then the cells were wash once with a TBS solution and were centrifuged at 1500rpm for 5min. 
The supernatant was discarded and the pellet was lysed with the lysis buffer, then stored at -
80°C before further measurement. For the measurement of phosphatase activity, the lysate 
was thawed on ice and desalted by gel filtration with a desalting column filled with activated 
resin. The desalted extracts were pipetted into microplates and were incubated with the 
substrate or the substrate plus inhibitors and EGTA as the negative control for 30min. The 
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samples were then incubated with 100μL BIOMOL® GREEN reagent for 30min in the dark. 
Next, the OD620nm of the mixture was measured with a TECAN M200 pro microplate reader. 
In principle, the free phosphates will react with the green reagent, the signal emitted by the 
end product can be detected as a reference to phosphatase activity. Data were presented as the 
raw OD620nm values from plate reading. 
 
6.2.13 Interleukin-8 secretion measurement 
Interleukin-8 (IL-8) secretion from melanoma cells was measured with the enzyme-linked 
immunosorbent assay (ELISA). The CXCL8/IL-8 DuoSet kit (R&D system) was purchased 
and used for the quantification of the IL-8 in the supernatant of culture medium according to 
manufacturer’s instruction.  
Briefly, the WM3734 cells were transfected with the siRNA against TMX1 or TMX3 by 
electroporation and were seeded into a 6-well plate at a density of 0.75x106 cells per well. 
After 48 hours, the cells were treated either with 10µg/mL human insulin, 100nM 
thapsigargin alone or 100nM thapsigargin and 100nM phorbol 12-myristate 13-acetate (PMA) 
together in 0.5mL medium for 12 hours. Then the medium was collected from the plates and 
was centrifuged at 1500 RPM for 5min. After centrifugation, the supernatant was collected 
and stored at −80 °C. For preparation of coated plates, the Falcon clear bottom 96-well plate 
was coated with 100µL of the capture antibody at a concentration of 4µg/mL overnight. 
Before using, the plates were blocked with 1% BSA in PBS for 1 hour. Then, 100µL of the 
supernatants were added to the wells and were incubated with a capture antibody for 2 hours. 
Next, the detection antibody was added after intensive washing. After 2 h incubation, the 
streptavidin-horseradish peroxidase and substrate solution containing hydrogen peroxide and 
tetramethylbenzidine (TMB) were added for the revelation. The absorbance of end products 
was measured with a ClarioStar® plate reader at 450nm, the absorbance at 570nm was 
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measured as a correction. All procedures were performed at room temperature. Between 
blocking, antibody incubations and substrate addition the wells were washed intensively with 
0.05% Tween®20 in PBS.  
 
6.2.14 Electron microscopy analysis of MAM parameters 
A monolayer of cells was fixed in 2% paraformaldehyde and 2% glutaraldehyde in 100mM 
sodium cocadylate buffer (pH 7.4) for 20 minutes. Then the cells were collected with scrapper 
as pellets. The pellets were fixed in osmium tetroxide 1% for the secondary fixation. The 
samples were washed and dehydrated, stained in 1% uranyl acetate. After the staining, the 
samples were treated with propylene oxide, and were then infused with embedding media 
(Embed 812); blocks were kept at 60 °C for hardening at least 48 h. The samples were then 
imaged using a digital camera mounted on a Philips 410 TEM, the images were processed 
with the “Mega View III” software. 
For the melanoma cell line 1205Lu, the distance between mitochondria and ER, and the 
length of ER mitochondria contact sits (MAM length) were measured and shown in 
nanometer units. Mitochondrial proximity to the plasma membrane was quantified by 
measuring the distance between the closest mitochondria to the plasma membrane. 
*The electron microscopy analyses were performed by Nasser Tahbaz and Lucas Mina, 
together with Prof. Dr. Thomas Simmen (Department of Cell Biology, University of Alberta, 
Canada).  
 
6.2.15 In vivo studies 
The mouse experiments received permission from the local governmental animal care 
committee (Landesamt für Verbraucherschutz des Saarlandes), and were performed in consent 
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to the German legislation on protection of animals and the National Institutes of Health Guide 
for the Care and Use of Laboratory Animals. The 8 weeks old male athymic nude NOD.Cg-
Prkdcscid Il2rgtm1WjI/SzJ (NSG) mice were purchased from Charles River Laboratories, 
Sulzfeld, Germany. For the experiment, mice were divided randomly to 3 groups (7 mice per 
group) for inoculation: (A) shRNA control (control), (B) shTMX1_1 (TMX1 kds 1), and (C) 
shTMX1_2 (TMX1 kds 2). Mice were maintained in ventilated cages under specific 
pathogen-free conditions with temperature and humidity control, light time per day was set to 
12h. All mice were maintained at the animal care facility of the Institute for Clinical and 
Experimental Surgery at Saarland University during experiment. Free access to tap water and 
standard pellet food were provided to all mice. The health status of mice was monitored by 
technician daily. Mice were each inoculated s.c. with 100,000 WM3734 cells suspended in a 
mixture of equal Matrigel (BD Matrigel™ Basement Membrane Matrix) and growth media. 
Tumor size was measured every 2-3 days by a single veterinarian who was blinded to the 
experimental groups, using a caliper. Tumor volumes were calculated using the formula: 
𝑉 =
𝜋 × 𝐿 ×𝑊2
6
 
Tumor samples with diameters larger than 15 mm before sacrifice were fixed and embedded 
in paraffin or frozen instantly after collection using liquid nitrogen. Immunoblots with tumor 
lysates were performed using 25 µg of total protein. 
*The mouse experiments were performed by Xin Zhang, Dr. Adina Vultur, Dr. Christina 
Körbel, in collaboration with Prof. Dr. Matthias W Laschke and Prof. Dr. Michael D Menger 
(Institute for Clinical and Experimental Surgery, Saarland University, Homburg-Saar). The 





6.2.16 Experimental data analysis and statistics 
The data obtained from all experiments were analyzed using TILL Vision, Zeiss Axiovision, 
Zeiss Zen, Biorad Quantity One, ImageJ with plugins and Microsoft Excel. The values are 
presented as mean ± SEM if not mentioned otherwise. The unpaired two-sided Student’s t test 
was used for data with normal distribution, the P-values are stated in the figure legends (* 





7.1 The expression analysis of TMXs and NFAT1 in human melanoma 
The pathogenesis of melanoma is a multiple-stage malignant transformation of the 
proliferative benign melanocytes to the invasive and metastatic melanoma cells. The 
acquisition of malignant competence is frequently caused by mutations, amplifications or 
deletions of certain precursor genes. Thus, genetic heterogeneity is one prominent 
characteristic of melanoma and hence there are only few biomarkers for this aggressive 
disease. In the current study, we investigated the role of TMX oxidoreductases and NFAT 
transcription factors in the human melanoma and addressed questions regarding if they are 
regulators of melanoma pathobiology and their potential connections with melanoma 
aggressive behavior.  
 
7.1.1 The mRNA expression of TMXs is elevated in melanoma cells 
We initiated our study with the assessment of expression status of TMXs proteins in the 
melanoma cells. The expression of TMX1 and TMX3 was quantified on the mRNA level with 
qPCR across a panel of distinct human melanoma cell lines. As shown in the Figure 1A and 
1B, on the mRNA level, TMX1 and TMX3 are generally expressed in the melanocytes, 
keratinocytes and melanoma cells. The expression of TMX1 and TMX3 in melanoma cells is 
heterogeneous at the first glance. However, compared with the normal melanocytes and 
keratinocytes, in around 70% of the melanoma cell lines analyzed, the expression of TMX1 is 
significantly up-regulated while 6 out of 10 cell lines have a higher expression of TMX3, 




Figure 1: mRNA expression of TMX1 and TMX3 in melanoma cell lines. (A) The mRNA 
expression of TMX1 quantified by the qPCR in a panel of melanocytes from two donors, 
keratinocyte and 11 melanoma cell lines. (B) The mRNA expression of TMX3 quantified by 
qPCR cross a panel of melanocytes from two donors, keratinocyte and 10 melanoma cell lines. 
(The data were normalized to the expression of TATA box bind protein and presented as 
mean±SEM of 3 independent experiments. The significance test was performed between 
individual melanoma cell lines and the two melanocyte cell lines.) 
 
7.1.2 The mRNA expression of NFAT1 is elevated in melanoma cells 
To analyze the expression of NFAT in melanoma, we first quantified the mRNA expression 
of all five NFAT isoforms in two cell lines with qPCR. The results in the Figure 2A suggest 
that the NFAT1 is the predominant isoform among all family members in our cell lines. Then 
we selected a panel of 10 melanoma cell lines and quantified the mRNA level of NFAT1 to 
establish a general view of its expression. Interestingly, in 9 out of 10 cell lines the NFAT1 is 
expressed on an astonishingly higher level when compared with the melanocytes and 
keratinocyte, in which NFAT1 is nearly undetectable (Figure 2B). This finding indicates a 




























































































































Figure 2: mRNA expression of NFAT in melanoma cell lines. (A) The mRNA expression 
of all NFAT isoforms quantified by the qPCR in two melanoma cell lines. (The data were 
normalized to the expression of TATA box bind protein and presented as mean of 3 
independent experiments.) (B) The mRNA expression of NFAT1 quantified by the qPCR in a 
panel of melanocytes from two donors, keratinocyte and 10 melanoma cell lines. (The data 
were normalized to the expression of TATA box bind protein and presented as mean±SEM of 
3 independent experiments. The significance test was performed between individual 
melanoma cell lines and the two melanocytes.) 
 
The higher mRNA expression of TMX and NFAT1 in melanoma cells indicates that the 
abundance of these proteins might also be elevated in melanoma. Therefore, the Western Blot 
analyses were performed with the lysates from 10 melanoma cell lines and melanocytes from 
two different donors. As shown in our publication (Panel 1C)(249), though the protein 
expression does not fully match the mRNA expression pattern shown in Figures 1 and 2, the 
WB clearly shows that TMX1 as well as NFAT1 protein are significantly higher in the 
melanoma cell lines compared with the melanocytes. Regarding the expression of NFAT1, it 
is not detected in the melanocytes while the expression in 9 out of 10 melanoma cell lines are 
relatively high. Interestingly, the WM1366 melanoma cell line, which originates from a 
vertical growth phase melanoma and has slower proliferation rate and low migration potential 





































































































NFAT1 mRNA and proteins are relatively high in the melanoma cell lines, their expression is 
relevant in the cultured cell lines.  
 
7.2 NFAT1 function is impaired by silencing of TMXs 
7.2.1 NFAT1 translocation is inhibited by silencing of TMXs 
In a previous study it was suggested that there is functional interaction between NFAT1 and 
TMX1, TMX3 in Hela cells. To explore how TMX1 and TMX3 could regulate NFAT1, we 
used a more detailed method based on the time-lapse fluorescent microscopy and GFP-tagged 
NFAT1 construct, in which the nuclear translocation of NFAT1 induced by stimulus can be 
tracked and assessed. First, we tested if the NFAT1 can be activated following a physiological 
stimulus such as insulin in the melanoma cells. Based on the expression analysis of TMXs 
and NFAT1, the WM3734 cells which have a high TMX1 and NFAT1 expression were used 
as the primary cell line. The Mel Juso cell line which has a high TMX1 expression but only 
moderate NFAT1 expression was used as a secondary cell line. By investigating these two 
cell lines, we also aimed to understand the impact of BRAF mutation in this context since the 
WM3734 is a BRAF V600E line and the Mel Juso is a BRAF wild type line. 
 As shown in Figure 3, the translocation of tagged NFAT1 can be induced by the addition of 
50 μg/ml human insulin in the ringer buffer with 0.25mM Ca2+. After the stimulation, the 
nuclear signaling of NFAT1-GFP was strongly elevated (quantified by Fn/F0, upper panel). 





Figure 3: Nuclear import of NFAT1 in melanoma cell. The NFAT1 translocation following 
50μg/ml human insulin stimulation was recorded with time-lapse fluorescent microscopy for 
900s in the WM3734 melanoma cells. (Upper panel: Quantification; Lower panel: 
representative images for the changes over the time course) 
 
Next, we used small interference RNA (siRNA) to silence the TMX1 and TMX3 on both cell 
lines for 48 hours, and then analyzed the NFAT1 translocation induced by Tg. As shown in 
Figure 4, the silencing of TMX1 and TMX3 inhibits the NFAT1 translocation in the WM3734 
and Mel Juso cells (Figure 4B and E) around 25%~40% (Figure 4C and F) which confirms 
that the TMX1 and TMX3 can inhibit the activation of NFAT1 in the melanoma cell lines 
regardless of their BRAF mutation status. To further confirm the validity of this signaling axis, 
the assay was performed on two additional melanoma cell lines (Figure 4J-M). The results 
show a consistent inhibition of NFAT1 translocation caused by silencing of TMX proteins, 
which indicates the mechanism under this signaling axis may be universal in melanoma cell 
lines. To test this, we overexpressed the NFAT1-GFP in the WM1366 cells, which do not 
have endogenous NFAT1 and performed the same assay. Nonetheless, the results show a 
similar pattern (Figure 4N-O). To summarize, these results show that NFAT1 is ready for 
activation in melanoma cells generally, and the activation is expression-independent.   
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Figure 4: NFAT1 translocation is inhibited following TMX silencing in melanoma cell 
lines. (A) and (D): Representative images from the recorded NFAT1 translocation movie on 
the TMX1 and TMX3 silenced WM3734 and Mel Juso cells. (B), (E), (J), (L), (N): Fold 
change of NFAT1 translocation from the live cell imaging experiment on a time course. (C), 
(F), (K), (M), (O): Quantification of the end point from the NFAT1 translocation experiment. 
Data were collected from 3 independent experiments and presented as mean±SEM. (The 
analyzed cell number N: WM3734, control=142, TMX1 kd=116, TMX3 kd=148; Mel Juso, 
control=75, TMX1 kd=47, TMX3 kd=67; WM938B, control=16, TMX1 kd=12, TMX3 
kd=27; WM164, control=46, TMX1 kd=56, TMX3 kd=44; WM1366, control=53, TMX1 
kd=49, TMX3 kd=63.) 
 
7.2.2 NFAT1 transcriptional activity is reduced by silencing of TMXs 
The inhibition of nuclear translocation of NFAT1 can lead to decreased transcriptional 
activity and a lower expression of downstream target genes. To check if the inhibition of 
NFAT1 translocation influenced the transcriptional activity of NFAT1, the production of 
interleukin-8 (IL-8) which was reported as a target gene of NFAT1 (242) was assessed by 
enzyme-linked immunosorbent assay (ELISA) assay. The WM3734 cells were transfected 
with siRNA against TMX1 and TMX3, after 48 hours the cells were incubated with either 
10μg/ml insulin, 100nM Tg or 100nM Tg and 100nM PMA together for 12 hours to induce 
the secretion of IL-8. As the end point, the growth medium was collected for the measurement 













































Figure 5: IL-8 secretion from melanoma cells is decreased following TMX silencing. The 
interleukin-8 secreted by TMX-silenced cells following different stimulation was measured 
with ELISA assay. The data are normalized as percentage of the control group and presented 
as mean±SEM of 4 independent experiments. 
 
As shown in Figure 5, the basal IL-8 production is inhibited by silencing of TMX1/TMX3 by 
up to 30~40% upon the stimulation with pre-conditioned medium which is supposed to 
contain growth factors secreted from the melanoma cells. Following stimulation with human 
insulin the IL-8 secretion is also inhibited by around 20%~30%. With more robust 
stimulations such as Tg and Phorbol 12-myristate 13-acetate (PMA), an activator of protein 
kinase C, the IL-8 production is even inhibited up to 20%~50%. These data confirm that the 
transcriptional activity of NFAT1 could be reduced by the knockdown of TMX proteins on 
both constitutional level or upon various stimulations. Based on these results, we conclude 
that the oxidoreductases TMX1 and TMX3 can regulate NFAT1 in melanoma cells as well as 
reported in Hela cells. The silencing of TMX1 and TMX3 thereby inhibit the activation of 
NFAT1 and impair the expression of downstream genes. 
 
7.3 Silencing of TMXs does not affect SOCE 
The activation of NFAT1 is canonically driven by the elevation of cytosolic Ca2+ following 
the signal transmission from plasma membrane. Therefore, we investigated if the silencing of 
TMX1/TMX3 affected the dynamics of cytosolic Ca2+ using live cell calcium imaging. The 
TMX1/TMX3 silenced cells were loaded with Fura 2, placed into a Ca2+ free ringer buffer 
and measured to assess the cytosolic Ca2+ resting levels. The cells were then treated with Tg 
to induce the depletion of the ER Ca2+ stores. A few minutes later, the cells were perfused 
with ringer buffer containing 1 mM Ca2+ for quantifying Ca2+ influx via the ORAI channels 
on the plasma membrane. At the end, the cells were perfused with Ca2+ free ringer buffer 
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again to monitor the clearance of cytosolic calcium. To our surprise, the results (Figure 6A) 
show that in WM3734 cells, the basal cytosolic Ca2+ level, the depletion of ER as well as the 
calcium influx via SOCE are not dramatically affected by the knockdown of TMX proteins 
(Figure 6B). These results indicate that the impairment of NFAT1 function caused by 
silencing of TMX1/TMX3 is not due to alterations in SOCE, which remains functional and 
intact.  
 
Figure 6: Cytosolic calcium measurement on WM3734 cells following TMX silencing. 
The cytosolic calcium was measured with ratiometric dye Fura-2 and live cell imaging on 
TMX-silenced WM3734 cells. Data are presented as mean±SEM. (The analyzed cell number 
N: control=30, TMX1 kd=49, TMX3 kd=52) 
 
7.4 Silencing of TMXs increases cellular ROS production 
The Ca2+ measurements imply that TMX1/TMX3 silencing-induced impairment of NFAT1 
function is through an alternative mechanism other than the disturbance of cellular Ca2+ 
dynamics. TMX oxidoreductases are involved in oxidative folding of proteins in the ER and 
their localizations are also confirmed in the related membrane network such as MAM. As 
mentioned before, such tethered membrane network is involved in the regulation of 
homeostasis of the organelles on both sides, accordingly it is plausible that these 
oxidoreductases could play a role in the regulation of ER-Mitochondria cross-talk and thus 
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affected the intracellular redox state with the genetically encoded protein sensor HyPer. First, 
we measured the cytosolic H2O2 level with HyPer3 probe in the TMX1/TMX3 silenced cells. 
As shown in Figure 7A, the transient knockdown of TMX1/TMX3 results in a significant 
increase of HyPer3 signal on both WM3734 and Mel Juso cells. After the measurement, the 
cells were incubated with 100µM N-acetylcysteine (NAC) to fully reduce the probe and set 
the ratio number to the background level for the calibration of the relative increase of signals. 
The quantification of HyPer signals shows that the cytosolic signal level is increased by more 
than 2 folds in the WM3734 cells, and around 20%~60% in the Mel Juso cells (Figure 7B and 
C). The signal of HyPer3 probes can also be affected by the pH of the compartment due to a 
structural imperfection, so we measured the cytosolic pH with the pH reporter SypHer probe 
which is a mutant of HyPer with critical cysteine replacement. The results show that there is 
no apparent change of cytosolic pH in both cell lines (Figure 7D and E). We also performed 
the same assay on the NFAT1-negative WM1366 cells (Figure 7F) to see if the induction of 
ROS is cell line-dependent, the result indicates that the induction caused by knockdown of 
TMX proteins is common in the melanoma cell lines. All together, these results show that the 
increase of cytosolic H2O2 level is caused by the knockdown of TMX proteins and the BRAF 
or NFAT1 expression is not relevant. Thus, we conclude that the knockdown of TMX 
proteins increases cellular ROS production in melanoma cells regardless of their BRAF 




Figure 7: Cytosolic H2O2 concentration was elevated by TMX silencing. (A) 
Representative images from the HyPer3 measurement on the TMX-silenced WM3734 cells 
and Mel Juso cells. (B, C and F) The quantification of the HyPer3 ratio values. Data are 
presented as mean±SEM of at least 3 independent experiments. (The analyzed cell number N: 
WM3734, control=168, TMX1 kd=209, TMX3 kd=192; Mel Juso, control=297, TMX1 
kd=343, TMX3 kd=440; WM1366, control=144, TMX1 kd=170.) (D, E and G) The 
quantification of the SypHer ratio values. Data are presented as mean±SEM of 3 independent 
experiments. (The analyzed cell number N: WM3734, control=142, TMX1 kd=153, TMX3 
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7.5 Silencing of TMXs inhibits NFAT1 activation via the oxidative 
modulation 
7.5.1 The NFAT1 translocation is redox dependent 
The signaling cascade of NFAT1 activation consists many proteins which can be regulated via 
reduction and oxidation reportedly. Based on our data, it is possible that the inhibition of 
NFAT1 activation by silencing of TMX1/TMX3 is caused by the elevation of cellular H2O2. 
Therefore, we tested the effect of H2O2 on the NFAT1 activity by exposing the cells to 
different concentrations of extracellular H2O2. As shown in Figure 8A, extracellular H2O2 
inhibits NFAT1 translocation in a dose-dependent manner in WM3734 melanoma cells. The 
evaluation of dose effect curve pointed an IC50 value at an extracellular concentration of 
approximately 13.2µM (Figure 8B). These results indicate that the NFAT1 translocation is a 
redox-dependent event and thus the elevation of cytosolic ROS can lead to its inhibition. 
 
Figure 8: The NFAT1 translocation is inhibited by extracellular H2O2 in a dose-
dependent manner. (A)The NFAT1 translocation is inhibited by pre-incubation with various 
concentrations of extracellular H2O2 to the WM3734 cells. Data are presented as mean of at 
least 4 cells from one experiment. (B) The quantification of the NFAT1 nuclear import by the 
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7.5.2 The inhibition of NFAT1 activation induced by silencing of TMX1 
can be reversed by antioxidants 
The thiol group of protein cysteine residues is very often a target for functional regulation via 
oxidation. The reductases in the cytosol reverse the oxidation using reducing resources in the 
cells such as glutathione and/or NADPH. Furthermore, the cells also have a well-balanced 
enzyme system for the degradation of ROS. The superoxide dismutase (SOD), peroxidases 
and catalases can catalyze the degradation of harmful ROS molecules and prevent oxidative 
damage. Thus, to test if the inhibition of NFAT1 caused by the silencing of TMX1/TMX3 can 
be reversed and prevented by antioxidants and ROS scavengers, the NFAT1 translocation 
assay was performed on the TMX1-silenced cells incubated with or without NAC (antioxidant 
and reducing reagent), PEG-catalase (ROS scavenger) and Dithiothreitol (DTT, reducing 
reagent). As shown in Figure 9A and B, NAC can partially rescue the inhibition of NFAT1 
translocation induced by the silencing of TMX1 in both cell lines. Moreover, DTT and 
catalase can also reverse the NFAT1 inhibition in TMX-silenced WM3734 cells (Figure 9C), 
while NAC alone does not affect the NFAT1 translocation. The result from Mel Juso cells 
shows a similar trend though the statistics are insignificant because of the low sample 
numbers (Figure 9D). Based on these results, we conclude that the inhibition of NFAT1 




Figure 9: The inhibition of NFAT1 activation induced by TMX1 silencing can be 
reversed by antioxidants. (A) and (B) The NFAT1 translocation on TMX1-silenced 
WM3734 and Mel Juso cells, the cells were incubated with 100µM NAC for 48 hours prior to 
the assay and recorded with live cell imaging. Data are presented as mean of 3 independent 
experiments. (The analyzed cell number N: WM3734, control=73, TMX1 kd=57, TMX1 
kd+NAC=63; Mel Juso, control=63, TMX1 kd=47, TMX kd+NAC=39.) (C) and (D) The 
Quantification of the end point from NFAT1 translocation assay on TMX1-silenced WM3734 
cells and Mel Juso cells pre-incubated with 100µM NAC (48h), 50U/mL PEG-catalase (48h), 
1mM DTT (20min). Data are presented as mean±SEM of 3 independent experiments (+NAC) 
and (+catalase), 1 experiment (+DTT). (The analyzed cell number N: WM3734, control=73, 
control+NAC=19, TMX1 kd=57, TMX1 kd+NAC=63, TMX1 kd+catalase=58, TMX1 
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7.5.3 Calcineurin is a redox-sensitive element of NFAT1 signaling pathway 
7.5.3.1 Calcineurin activity is inhibited by silencing of TMXs 
Several elements of the NFAT1 signaling pathway can be redox regulated. In principle, the 
ORAI channels on the plasma membrane consist of cysteine residues, which are prone to 
oxidation; the methionine oxidation of calmodulin could also be involved as well as the 
phosphatase calcineurin, which contains a reactive cysteine in its catalytic core and multiple 
cysteine residues around the catalytic site. Calcineurin dephosphorylates NFAT1 to initiate 
the nuclear transportation of NFAT1, thus it plays a critical role in the signaling cascade. 
Therefore, first we explored if calcineurin was the target for the oxidative modulation induced 
by the silencing of TMX1/TMX3 with a genetically encoded sensor CaNAR2-cyto. This 
protein sensor contains a sequence with dephosphorylation sites similar to the NFAT proteins 
and is therefore a mimic of natural target of calcineurin. Upon the dephosphorylation the 
configuration of this sensor changes, which leads to the decrease of distance between the 
CFP/YFP pair resulting an enhancement of FRET signal. The changes of FRET signal ratio 
indirectly report the phosphatase activity of calcineurin. As shown in Figure 10A, the 
silencing of TMX1/TMX3 leads to suppressed calcineurin activity, which is activated by Tg-
induced calcium influx. The quantification of the basal levels and post-activation levels of 
calcineurin activity show that the silencing of TMX1/TMX3 decreases the basal as well as the 
induced calcineurin activity significantly in comparison with the control group (Figure 10B 
and C). To test if the inhibition is indeed due to oxidative modification, the cells were 
incubated with NAC after the siRNA transfection. The results in Figure 10 D and E show that 
indeed NAC restores the inhibited calcineurin activity in TMX-silenced WM3734 cells. The 
basal calcineurin activity at resting level (Figure 10D) as well as the maximum activity upon 
activation (Figure 10E) is restored to nearly the same level compared with control group. 
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According to these results, we conclude that the inhibition of NFAT1 nuclear import is caused 
by the inhibition of calcineurin activity. 
 
Figure 10: The phosphatase activity of calcineurin is inhibited by TMX silencing. (A) 
The cytosolic calcineurin activity of TMX-silenced melanoma cells was measured with 
CaNAR2-cyto protein sensor upon 1µM Tg+1µM Ionomycin induced calcium influx in 
Ringer’s buffer with 1mM free Ca2+ and shown as curves on a time course. Data are presented 
as mean of 3 independent experiments. (The analyzed cell number N: control=49, TMX1 
kd=48, TMX3 kd=63.) (B) The quantification of the basal calcineurin activity in WM3734 
cells at resting state. (C) The quantification of the maximum calcineurin activity induced by 
Tg+Ionomycin, the ratio values from basal activity are subtracted from the maximum ratio 
value. (D) and (E) The quantification of basal and maximum calcineurin activity measured on 
the TMX1-silenced WM3734 cells with/without 100µM NAC pre-incubation for 48 hours. 
Data are presented as mean±SEM of 2 independent experiments. (The analyzed cell number 








































































































































































































































7.5.3.2 Calcineurin activity could be inhibited by H2O2  
To further test the redox sensitivity of calcineurin, we exposed melanoma cells to various 
concentration of H2O2 for 5 min before the stimulation with Tg in Ringer’s buffer with 1mM 
free Ca2+. We again used CaNAR2-cyto sensor to determine calcineurin activity. As shown in 
Figure 11A, the calcineurin activity shows a H2O2 concentration dependence in the time-lapse 
assay. The normalized results show that the maximum calcineurin activity is inhibited by the 
extracellular H2O2 in a dose-dependent manner (Figure 11B). In all, these data indicate that 
calcineurin activity depends on the intracellular redox state; thus, the TMX silencing induced 
excessive ROS is responsible for the inhibition of NFAT1 nuclear import. 
 
Figure 11: Calcineurin activity is inhibited by H2O2 in melanoma. (A) Mel Juso cells were 
pre-incubated with different concentration of extracellular H2O2 in Ringer’s buffer containing 
1mM free Ca2+ for 5min, then cells were stimulated with Tg and the cytosolic calcineurin was 
measured with CarNAR2-cyto sensor. Data is normalized according the basal calcineurin 
activity and presented as the mean of at least 20 cells. (B) The quantification of maximum 


























































































7.6 Mitochondria are major source for ROS generation following TMX 
silencing 
7.6.1 Silencing of TMXs does not induce ER stress 
Based on our results from cytosolic ROS measurements, the elevated cellular H2O2 levels in 
melanoma cells indicate that the redox balance is disturbed by silencing of TMX1 or TMX3. 
However, the source of this ROS production remains elusive so far. The TMX1 and TMX3 
are anchored within the ER membrane with the active site hanging in the ER lumen. It is 
possible that the knockdown of TMX1/TMX3 might disturb the oxidative folding of proteins 
and lead to the ER stress, which may consequently induce oxidative stress in the cytosol in 
extreme cases. To test this theory, we investigated if the silencing of TMX induced ER stress 
in melanoma cell lines by measuring ER stress markers such as XBP1 splicing products, Bip 
and disulfide isomerase protein expression (PDI). The splicing product of X-box binding 
protein 1 (XBP1) was quantified by qPCR, and the protein expression of protein disulfide 
isomerase and binding immunoglobulin protein (BiP) were assessed with WB. As shown in 
Figure 12A, compared with the positive control group which was treated with thapsigargin for 
4 hours, the XBP1s mRNA level is not increased in TMX1/TMX3 silenced melanoma cells. 
Furthermore, the Figure 12B shows that the PDI and BiP expression are also not elevated 
following TMX1/TMX3 silencing (Figure 12B). These findings indicate that silencing of the 
TMX proteins, despite their important role in oxidative folding, does not lead to significant 




Figure 12: TMX silencing does not trigger ER stress in melanoma cells. (A) The splicing 
product of XBP1 was quantified by qPCR from samples collected 48 hours after the siRNA 
transfection, the positive control was treated with 1µM Tg for 4 hours to induce the ER stress. 
Data are presented as mean of 2 independent experiments. (B) The expression of PDI and BiP 
proteins was quantified by Western Blot from the lysates collected 48 hours after the siRNA 
transfection, the GAPDH was used as the loading control. The blots are representative images 
of two independent experiments.  
 
7.6.2 Silencing of TMX1 does not affect ER redox homeostasis 
To further check if the ER redox homeostasis was disturbed by the silencing of TMX, we 
measured ER H2O2 levels with the genetically encoded protein sensor ER HyPer in TMX1-
silenced WM3734 and Mel Juso cells. The cells were transfected with the siRNA against 
TMX1 and scrambled control; and the plasmids of ER HyPer were transfected 24 hours prior 
to the measurement. Forty-eight hours after the siRNA transfection, the cells were placed into 
a Ringer’s buffer with 0.25mM Ca2+ and imaged. As shown in Figure 13 (A and B), the 
silencing of TMX1 increases the ER H2O2 level moderately in both cell lines. However, this 
result needs to be interpreted with particular care. The ER lumen is a highly oxidizing 
compartment due to its function in oxidative folding of proteins. Hence, the majority of the 
HyPer probes within the ER lumen are at least partially oxidized (Figure 13C). Nonetheless, 
























































suggest that the ER lumen is very likely not the main source of ROS following the silencing 
of TMX1/TMX3, though the contribution can’t be fully excluded.  
 
Figure 13: The ER lumen is not a major source of H2O2 in melanoma cells following 
TMX1 silencing. (A) and (B) The quantification of results from ER HyPer experiment on the 
TMX1-silenced WM3734 cells and Mel Juso cells 48 hours after the siRNA transfection. 
Data are presented as mean±SEM of 3 independent experiments. (The analyzed cell number 
N: WM3734, Control=169, TMX1 kd=179; Mel Juso, Control=211, TMX1 kd=249.) (C) and 
(D) DTT and H2O2 titration of ER HyPer probes on native WM3734 cells. Data are presented 
as mean±SEM of 4 cells from 1 experiment.  
 
7.6.3 Mitochondrial ROS is increased by silencing of TMXs 
TMX1 and TMX3 are enriched in the MAM section of ER and mitochondria contact sites 
reportedly. These contact sites have profound influence on many functions of the two 
























































































































which might induce generation of ROS. We next measured H2O2 levels in mitochondria with 
the genetically encoded protein sensor mito-HyPer2 in WM3734 and Mel Juso cells. As seen, 
the silencing of TMX1/TMX3 results in a significant increase of HyPer signal ratio (Figure 
14A) in both cell lines. The quantification of the HyPer probe ratio shows that silencing of 
TMX1 and TMX3 induced dramatic H2O2 generation on the WM3734 and Mel Juso cells 
(Figure 14B and C). Using a mito-SypHer sensor we monitored the mitochondrial pH under 
the same conditions described above. Our results show the silencing of TMX1/TMX3 does 
not cause overt changes of mitochondrial pH (Figure 14D and E). 
 
Figure 14: TMX silencing induces significant increase of mitochondrial ROS. (A) 
Representative images of mito-HyPer2 measurements on TMX-silenced WM3734 and Mel 
Juso cells. (B) Quantification of mito-HyPer2 ratio on the WM3734 cells 48 hours after the 
siRNA transfection. Data are presented as mean±SEM of at least 3 independent experiments. 
(The analyzed cell number N: control=546, TMX1 kd=510, TMX3 kd=621.) (C) 
Quantification of mito-HyPer2 ratio on the Mel Juso cells 48 hours after the siRNA 
transfection. Data are presented as mean±SEM of at least 3 independent experiments. (The 













































































































































































mito-SyPer ratio on the WM3734 cells 48 hours after the siRNA transfection. Data are 
presented as mean±SEM of 3 independent experiments. (The analyzed cell number N: 
control=87, TMX1 kd=85, TMX3 kd=105.) (D) Quantification of mito-SyPer ratio on the Mel 
Juso cells 48 hours after the siRNA transfection. Data are presented as mean±SEM of 3 
independent experiments. (The analyzed cell number N: control=74, TMX1 kd=73, TMX3 
kd=83.) 
 
7.6.4 Elevated mitochondrial ROS is caused by altered mitochondrial 
metabolism 
7.6.4.1 Mitochondrial calcium level is increased by TMX1 silencing 
The mitochondrial ROS generation is coupled to the mitochondrial oxidative phosphorylation 
and respiration activity. The irregular mitochondrial ROS generation is frequently caused by 
either the electron leakage from the disrupted of electron transfer chain (ETC) or a hyper-
activation of oxidative phosphorylation which produces ROS molecules as a “by-product” 
(162, 250). The accumulation of mitochondrial Ca2+ ([Ca2+]mito) can drive the activation of the 
mitochondrial metabolic machinery and enhance the ATP synthesis. Hence, because of the 
dependence of ATP synthesis on [Ca2+]mito, the [Ca2+]mito is a good indicator for mitochondrial 
metabolic activity. Accordingly, we measured mitochondrial calcium dynamics with a 
genetically encoded Ca2+ sensor 4mt-D3cpV in WM3734 cells with stable TMX1 knockdown. 
As shown in Figure 15A, the silencing of TMX1 leads to an increase in resting [Ca2+]mito as 
well as in SOCE-induced  [Ca2+]mito influx. The quantification data in (Figure 15B) shows the 
basal [Ca2+]mito is increased slightly by the silencing while the uptake is increased 
significantly compared with the control (Figure 15C). However, due to the low Kd of 4mt-
D3cpV, the sensor could be saturated and will no longer answer to the elevation of Ca2+ upon 
a dramatic change. To address this issue, we used alternative genetically encoded protein 
sensor 4mt-TNXL, which has a higher Kd  and performed the same measurements as with 
4mt-D3cpV. As shown in Figure 15D, the [Ca2+]mito dynamics show a similar pattern, thus 
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confirm that the [Ca2+]mito levels are increased by of TMX1 silencing. Furthermore, the 
quantification data show the basal [Ca2+]mito is increased significantly (Figure 15E) as well as 
mitochondrial  Ca2+ uptake (Figure 15F).  
 
Figure 15: Mitochondrial calcium uptake is increased following TMX1 silencing. (A) The 
mitochondrial Ca2+ uptake was measured with genetically encoded protein sensor 4mt-D3cpV 
on WM3734 cells with a stable expression of shRNA against TMX1. Data are presented as 
mean of 3 experiments on a time course. (B) Quantification of the basal mitochondrial Ca2+ 
level from data in (A). Data are presented as mean±SEM. (The analyzed cell number N: 
control=62, TMX1 kd=45.) (C) Quantification of the mitochondrial Ca2+ uptake (basal-
plateau) from data in (A). Data are presented as mean±SEM. (The analyzed cell number N: 
control=62, TMX1 kd=45.) (D) The mitochondrial Ca2+ uptake was measured with 
genetically encoded protein sensor 4mt-TNXL on WM3734 cells with a stable expression of 
shRNA against TMX1. Data are presented as mean of 1 experiment on a time course. (E) 
Quantification of the basal mitochondrial Ca2+ level from data in (D). Data are presented as 
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the mitochondrial Ca2+ uptake (basal-plateau) from data in (D). Data are presented as 
mean±SEM. (The analyzed cell number N: control=94, TMX1 kd=83.) 
 
Next, we used a more detailed protocol, which separates the calcium transfer from ER and 
from PM into mitochondria. The cells were transiently transfected with siRNA against TMX1 
and D3cpV sensor as before. Forty-eight hours later the cells were imaged in Ringer’s buffer 
with 0 mM Ca+ for a few seconds. Thereafter, the ER Ca2+ store depletion was triggered with 
Tg, in order to monitor calcium transfer from ER to mitochondria. To evaluate the PM-
mitochondria Ca2+ transfer the extracellular Ca+ was elevated to 1 mM. As shown in Figure 
16A-C, the ER-mito transfer is decreased albeit the PM-mitochondria Ca2+ transfer is 
increased by silencing of TMX1-silenced cells. Thus, our data suggest that the increased 
calcium transfer from the plasma membrane is largely responsible for the increased [Ca2+]mito  
following TMX1 silencing, and the transfer from ER is restrained. Taking the difference 
between the extracellular compartment and the ER into account, the overall effect of TMX1 
silencing should lead to an elevated mitochondrial calcium dynamic. These results also hint 
that mitochondrial metabolism should be enhanced in due by the elevation of mitochondrial 
calcium level.  
 
Figure 16: The PM to mitochondria calcium transfer is increased following TMX1 





















































































sensor 4mt-D3cpV on WM3734 cells 48 hours after the siRNA transfection. Data are 
presented as mean of 3 independent experiments on a time course. (B) Quantification of the 
ER-mito calcium transfer from data in (A). (The analyzed cell number N: Control=124, 
TMX1 kd=109.) (C) Quantification of the PM-mito calcium transfer from data in (A). (The 
analyzed cell number N: Control=124, TMX1 kd=109.) 
 
7.6.4.2 Mitochondrial ATP is elevated by TMX1 silencing 
To test our speculations on the role of TMX1 on mitochondrial metabolic activity, we 
measured mitochondrial ATP in the stable knockdown cell lines with a genetically encoded 
mitochondria targeted ATeam1.03 protein sensor. The results shown in Figure 17A confirm 
that the mitochondrial ATP level is higher in the TMX1-silenced cell lines. The quantification 
data in Figure 17B depicts a significant increase in the resting mitochondrial ATP in both 
TMX1-downregulated melanoma lines. 
 
Figure 17: The basal mitochondrial ATP level is increased following TMX1 silencing. (A) 
The representative images from mito-ATeam1.03 measurements in WM3734 cells stably 
expressing shRNA against TMX1. Bars represent 10µm. (B) Quantification of basal 
mitochondrial ATP data, all data were normalized to the Control and shown in percentage. 
Data are presented as mean±SEM of 3 independent experiments. (The analyzed cell number 










































Additionally, to confirm the mitochondrial metabolism is altered by the silencing of TMX1, 
the oxygen consumption rate (OCR) of TMX1-silenced WM3734 cells was examined with a 
Seahorse XF96 extracellular Flux Analyzer by our collaborators in the Biochemistry 
department. As shown in their results (Panel EV5G, H, I)(249), the TMX1-silenced WM3734 
cells show a higher basal OCR as well as maximal OCR compared with the control. Although 
from the quantification data, one of the clones does not show a significant increase of basal 
and maximal respiration (TMX1 knockdown stable 1, TMX1 kds1), the overall trend shows a 
strong increase of OCR which confirms that the capacity of oxidative phosphorylation is 
increased following silencing of TMX1. 
Summarized, our data shows that the silencing of TMX1 can alter the mitochondrial 
metabolism via an increase of the mitochondrial calcium uptake, which further boosts the 
capacity of mitochondrial respiration. The higher mitochondrial respiration produces more 
ATP and increases the rate of ROS generation. 
 
7.6.5 TMX1 silencing alters mitochondrial morphology  
The altered mitochondrial Ca2+ levels could be caused by several factors including the up-
regulation of mitochondrial calcium uniporter (MCU) or other channels, but the proximity of 
mitochondria to the calcium stores and channels also plays an important role. Since the 
calcium data show a strong increase of PM to mitochondria calcium transfer while the ER to 
mitochondria calcium transfer is reduced, the positioning of mitochondria and communication 
between mitochondria and ER in this case may be critical for the outcome. The similar 
observations were reported before, that during T cell activation, the cell polarization causes 
re-organization of the mitochondrial network to facilitate mitochondrial calcium uptake (251), 
and the sustained absorption of calcium by mitochondria can extend the calcium influx via 
plasma membrane and activation of T cells. In these observations, the structural changes are 
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initiative and critical for the following response in calcium signaling. To examine if the 
silencing of TMX1 caused any structural and morphological alterations of mitochondria, the 
mitochondrial morphology in the TMX1-silenced stable melanoma cell lines was examined 
with 3D confocal fluorescent microscopy by our collaborator Dr. Miso Mitkovski. As shown 
in Panel 5(G, H)(249), the silencing of TMX1 leads to a significant increase of mitochondrial 
total volume and surface, alterations that could lead to a higher exposure of mitochondria to 
the surrounding environment. Thus, the area of mitochondria exposed to the plasma 
membrane might be affected by the knockdown of TMX1. Further examination of the 
mitochondrial content in the vicinity of the plasma membrane with ImageJ software showed 
Panel 5(I, J)(249) that the area occupied by peripheral mitochondria is increased more than 
two folds in the TMX1 silenced cells. These data suggest the knockdown of TMX1 may lead 
to re-organization of mitochondria network and alteration of mitochondria morphology. 
Based on the analysis of mitochondrial calcium uptake and morphology, it is postulated that 
the alteration of MAM structure might be responsible for the re-organization of mitochondria 
upon TMX1 knockdown. Therefore, the MAM structure and the mitochondrial positioning in 
the stable knockdown cells were investigated by our collaborators in Canada using electron 
microscopy. The quantified data show that the distance between mitochondria and PM is 
reduced by nearly 40% (Figure 18B), while the distance between mitochondria and ER is 
increased by nearly 25% (Figure 18C) in the TMX1-silenced melanoma cells. And the MAM 
length is shortened by nearly 30% (Figure 18D). These data suggest the knockdown of TMX1 
shortens MAM length and causes a positioning shift of mitochondria network from ER 
adjacent area to the plasma membrane peripheral in melanoma cells (Figure 18A). Based on 
these findings, we conclude that the disturbance of MAMs and the mitochondrial re-
positioning caused by the knockdown of TMX1 enhance the exposure of mitochondria to PM, 
ultimately lead to a higher exposure of mitochondria to calcium hotspots near the PM. 
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Consequently, the plasma membrane-derived mitochondrial Ca2+ uptake is increased upon 
SOCE activation.   
 
Figure 18: Mitochondrial repositioning towards the plasma membrane in melanoma 
cells following TMX1 silencing. (A) Representative images of the electron microscopy from 
TMX1-silenced 1205Lu cells. (B) Quantification of the distance between mitochondria and 
plasm membrane. Data are presented as mean±SEM. (The analyzed cell number N: 
Control=100, TMX1 kds=100.) (C) Quantification of the distance between mitochondria and 
ER. Data are presented as mean±SEM. (The analyzed cell number N: Control=60, TMX1 
kds=60.) (D) Quantification of MAM length. Data are presented as mean±SEM. (The 
analyzed cell number N: Control=60, TMX1 kds=60.) 
*The establishment of TMX1 stable knockdown cell line is done by Xin Zhang. The electron 
microscopy experimental data were generated by Nasser Tahbaz, Lucas Mina and Prof. Dr. 
Thomas Simmen, data processing was done by Xin Zhang. 
 
The disturbance of MAM structure can cast strong influences on the function and homeostasis 
of it reportedly. The structural studies already proved that the TMX1 silencing led to 
mitochondria repositioning and morphology changes, yet we searched for a direct observation 
of the redox homeostasis in MAM upon the silencing of TMX proteins. The MAM targeted 
HyPer sensor (unpublished work) was used to measure the H2O2 level upon a 48h transient 
silencing of TMX1 and TMX3. As shown in Figure 19A, although some of the protein 
sensors are retained in part of the whole mitochondria to ER network, the expression of this 







































































Figure 19B show that indeed the silencing of TMX1 or TMX3 induces a relatively significant 
increase of H2O2 in MAM domain.   
 
Figure 19: Mitochondrial repositioning disturbed redox homeostasis in MAM. (A) 
Representative image of the MAM-HyPer protein sensor in WM3734 cells. (B) Quantification 
of the H2O2 level in MAM upon transient silencing of TMX1 and TMX3. Data are presented 
as mean±SEM of 2 independent experiments. (The analyzed cell number N: Control=17, 
TMX1 kd=15, TMX3 kd=10.) 
 
In summary, our data on mitochondrial function and morphology suggest that the silencing of 
TMX1 can alter the mitochondrial morphology and positioning which lead to an increase of 
mitochondrial calcium uptake, higher metabolic activity and ultimately the elevated 
mitochondrial ROS production. The disturbance also caused a disruption of MAM redox 
homeostasis directly, leading to higher level of H2O2 accordingly. Our findings highlight 
TMX oxidoreductases as important elements in regulating the MAM stability and 
mitochondrial architecture.  
 
7.7 NOX4 is an alternative source of ROS 
The NADPH oxidase (NOX) family enzymes are a set of oxidases that generate superoxide 






































mitochondria are major intracellular sources of ROS. The NOX4 has been suggested to be a 
membrane bound protein localized in PM, mitochondria and ER (252-255). Accordingly, we 
asked if NOX4 played a role in the ROS induction by upon TMX1 silencing. For this purpose, 
we measured cellular H2O2 concentration in TMX1-silenced cells with additional NOX4 
knockdown or treatments with the NOX4 inhibitor GKT137831. Our results show that both 
silencing of NOX4 or suppression of its activity lead to reduction in ROS levels in TMX1-
silenced cells (Figure 20A-B). Importantly, the knockdown or the inhibition of NOX4 causes 
only a minor change of cellular pH in WM3734 cells (Figure 20C).  
 
Figure 20: The NOX4 is an alternative source of excessive cellular ROS. (A) 
Representative ratiometric images of HyPer3 measurement on the WM3734 cells transfected 
with TMX1 siRNA, both TMX1 siRNA and NOX4 siRNA or treated with the NOX4 
inhibitor GKT137831 (140nM) for 48 hours. Bars represent 10µM. (B) The quantification of 
the HyPer3 data. Data are presented as mean±SEM of 3 independent experiments. (The 
analyzed cell number N: Control=837, TMX1 kd=888, TMX1 kd+NOX4 kd=793, 
TMX1+GKT=844.) (C) The quantification of the SypHer data as pH control for HyPer3. Data 
are presented as mean±SEM of 3 independent experiments. (The analyzed cell number N: 
Control=265, TMX1 kd=233, TMX1 kd+NOX4 kd=187, TMX1+GKT=194.) 
 
In sum, we conclude that the elevation of cytosolic ROS in the TMX1/TMX3-silenced cells is 
caused by the increased ROS production both from mitochondria and NOX4, though the 
































X1 kd + NO
X4 kd
TM










Control TMX1 kd TMX1 kd 
+NOX4 kd

































X1 kd + NO
X4 kd
TM











7.8 TMX-ROS-NFAT1 signaling axis controls melanoma behavior 
7.8.1 TMX-ROS-NFAT1 axis promotes melanoma proliferation  
The TMX1 was reported as a suppressor of melanoma previously but notably only in a single 
cell line based study (228). The role of NFAT1 in melanoma was mostly yet to be revealed. 
Since the known literature never investigated these two elements in an integrative way on 
melanoma pathology, we next proceeded to investigate the impact of TMX-ROS-NFAT1 axis 
on melanoma pathology. Our data indicated that TMX1 and NFAT1 might have a close 
association with melanoma progression; hence we first started with examining the 
proliferation of melanoma cells upon suppression of TMX1/3 and NFAT1.  
As shown in Figure 21A, the silencing of TMX1/TMX3 significantly inhibits the proliferation 
of WM3734 and Mel Juso cells (19% and 21% for TMX1; 29% and 39% for TMX3) around 
at 48 hours after the siRNA transfection while the inhibition on the WM1366 cells (non-
NFAT1 expression line) is less pronounced (10% for TMX1; 8% for TMX3). To test if 
oxidative stress controls these effects on cell proliferation, the cells were treated with 
antioxidants. NAC and the mitochondria targeted antioxidant mTEMPO were used on the 
TMX1-silenced WM3734 cells. Figure 21C shows that both antioxidants can reverse the 
TMX1-silencing induced inhibition of proliferation, but NAC has a stronger potency. The 
three cell lines used for our experiment have different BRAF (mutation), NRAS (mutation) 
and NFAT1 (expression) status, so the data hint for a more general mechanism among 
melanoma cells. Based on these results, we conclude that the TMX-NFAT1 axis controls 
proliferation of melanoma cells regardless of their mutation status. Notably, NFAT1 
expression affects the potency of TMX knockdown induced inhibition of proliferation, the 
inhibition of its activation also causes additional suppression of melanoma proliferation.  
The siRNA mediated silencing usually provides only a very limited time window to examine 
the role of a certain protein. In order to examine the long-term effects of TMX silencing, we 
98 
 
measured proliferation in melanoma cells with stable TMX1 downregulation. As shown in 
Figure 21B, the proliferation of two cell lines with stable knockdown of TMX1 is also 
suppressed by 30%~40%, a finding that confirms that silencing of TMX proteins causes 
inhibition of melanoma cell proliferation in 2D culture in both short and long periods.  
 
Figure 21: Proliferation of melanoma cells is inhibited following TMX silencing. (A) The 
proliferation was measured by cell titer blue assay on WM3734, Mel Juso and WM1366 cells 
48 hours after transfection of siRNA against TMX1 and TMX3. Data are normalized to the 
percentage of control and presented as mean±SEM of at least 4 independent experiments. (B) 
The proliferation was measured by cell titer blue on WM3734 cells and 1205Lu cells stably 
expressing shRNA against TMX1. Data are normalized to the percentage of control and 
presented as mean±SEM of 3 independent experiments. (C) The NAC and mTEMPO were 
used to rescue the proliferation inhibition induced by TMX1 kd on WM3734 cells. After the 
siRNA transfection, the antioxidants were added and incubated with the cells for 48 hours, the 
proliferation was assessed with cell titer blue assay. Data are normalized to the percentage of 


































































































Next, we tested if silencing of NFAT1 could induce similar effects on melanoma cell 
proliferation. Our data show that silencing of NFAT1 mediated by siRNA significantly 
inhibits the proliferation of both WM3734 and MelJuso melanoma cell lines (Figure 22A). To 
further test the role of NFAT1, we treated the cells with various concentrations of 
dipyridamole, a drug that disrupts NFAT1-calcineurin interaction. Our results show an 
inhibition of melanoma cell proliferation in a dose-dependent manner during a period of 72 
hours by disrupting NFAT1 docking to calcineurin (Figure 22B). In all, these data suggest 
that TMX1/TMX3 and NFAT1 promote melanoma cell proliferation, and suppression of these 
proteins has a negative effect on the proliferation of melanoma cells in 2D culture. 
 
Figure 22: The proliferation of melanoma cells is inhibited by suppression of NFAT. (A) 
The proliferation was measured with cell titer blue assay on WM3734 cells and Mel Juso cells 
24 hours after the transfection with siRNA against NFAT1. Data are normalized to the 
percentage of control and presented as mean±SEM of 3 independent experiments. (B) The 
proliferation was measured with cell titer blue assay on WM3734 cells and Mel Juso cells 72 
hours after treatment with various concentration of Dipyridamole. Data are normalized to the 
percentage of control and presented as mean±SEM of 3 independent experiments. 
 
7.8.2 TMX-ROS-NFAT1 axis promotes melanoma migration 
Cellular invasiveness is the important parameter correlated with progression of cancers (256). 






























































cells. Figure 23A shows that silencing of TMX1/TMX3 inhibits migration of WM3734 cells 
by up to 35% and 50%, respectively. But this effect was not observed in the NFAT1-negative 
WM1366 cells, which indicates that NFAT1 may be more critical in the regulation of 
migration. Moreover, the inhibition of melanoma cell migration is reversed by NAC and 
mTEMPO suggesting involvement of redox regulation (Figure 23B). Furthermore, Inhibition 
of NFAT1-calcineurin interaction or calcineurin activity by dipyridamole or Cyclosporine A 
also suppresses the migration of WM3737 and 1205Lu cells significantly (Figure 23C). As 
depicted, the Dipyridamol treatment reduces WM3734 and 1205Lu cell migration by around 
25% and 45%; Cyclosporine A inhibits the migration by nearly 40% in WM3734 cells and 30% 
in 1205Lu cells. The invasion measurements also show that stable knockdown of TMX1 may 
inhibit the invasion of WM3734 cells into Matrigel (Panel 6H) (249). Taken together, our data 
suggest that the TMX1, TMX3 and NFAT1 promote melanoma cell migration and invasion 




Figure 23: The migration of melanoma cells is inhibited following TMX silencing or 
suppression of NFAT, calcineurin. (A) The migrations of TMX-silenced WM3734 and 
WM1366 cells were assessed with transwell migration assay 48 hours after the siRNA 
transfection. Data are normalized to the percentage of control and presented as mean±SEM of 
3 independent experiments. (B) The effect of NAC (100µM) and mitochondria targeted 
antioxidant mTEMPO (100nM) on migration of TMX1-silenced WM3734 was assessed with 
transwell migration assay 48 hours after the siRNA transfection and antioxidant treatment. 
Data are normalized to the percentage of control and presented as mean±SEM of 3 
independent experiments. (C) The migration of melanoma cells treated with NFAT inhibitor 
(Dipyridamol, 40µM) and calcineurin inhibitor (CsA, 2µM) for 48 hours was assessed with 
transwell migration assay. Data are normalized to the percentage of control and presented as 


























































































7.8.3 TMX1 silencing does not affect BRAF-inhibitor sensitivity in 
melanoma 
The oncogenic BRAF mutation and downstream hyperactive MAPK signaling pathway are 
proved to be prevalent in melanoma (257, 258). The combination of BRAF and/or MEK 
inhibitors is thus often used for treating melanoma. Thus, we tested if the knockdown of TMX 
proteins had any impact on the BRAF and MAPK signaling and cell drug sensitivity. To this 
end, we quantified the proliferation of two WM3734 cell clones stably expressing shRNA 
against TMX1 following treatment with BRAF- (Vemurafenib) and/or MEK inhibitor 
(Trametinib). As shown in Figure 24A and B, at the clinically relevant concentrations, the 
drugs elicit the same proliferation inhibition in knockdown cells compared with control cells, 
in other words, the silencing of TMX1 does not seemingly increase any advantages over these 
two inhibitors. Hence, we conclude the effects induced by knockdown of TMX proteins are 
very likely BRAF/MEK independent, and that the TMX-ROS-NFAT axis controls melanoma 
cells regardless of their BRAF/NRAS mutational status. 
 
Figure 24: TMX1 silencing does not affect BRAF and MEK resistance of melanoma cells. 
(A) The proliferation was measured with celltiter blue assay on WM3734 cells with stable 
knockdown of TMX1 48 hours after the treatment with different concentrations Vemurafenib. 
Data are normalized to the percentage of control and presented as mean±SEM of 3 
independent experiments. (B) The proliferation was measured with celltiter blue assay on 
























































concentrations of Trametinib. Data are normalized to the percentage of control and presented 
as mean±SEM of 3 independent experiments. 
 
7.8.4 TMX1 silencing affects melanoma tumor growth in vivo 
Our in vitro data strongly support that TMX1, TMX3 and NFAT1 control melanoma 
proliferation and migration. But regarding the in vivo environment such as solid tumor, there 
are many factors which can lead to a different result. We thus subcutaneously injected 
WM3734 cells stably expressing shRNA against TMX1 into the immunosuppressed NOD-
SCID-IL2-c-null (NSG) mice. As shown in figure 25, in the first 19 days after the inoculation 
the tumor growth was significantly slower in the mice with TMX1-silenced cells resulting in a 
significantly smaller tumor volume compared with the control (Figure 25A, B). Surprisingly, 
by the end of the experiment at 45 days, the tumor volume of TMX1-silenced cells was no 
longer inhibited (Figure 25C and D), and the rebound of tumor growth from both clones was 
apparent. These data indicate that silencing of TMX1 suppresses melanoma growth both in 
vitro and in vivo, but also implies that melanoma cells could adapt in an in vivo setting 
through re-wiring of signaling pathways or activating other alternative mechanisms. To 
address the possible adaptive mechanisms, the western blotting was performed with the tumor 
lysates collected at the end of mouse experiment. The results exclude the possibility that the 
rebound of tumor growth is caused by the recovery of TMX1 protein expression by showing a 
still suppressed level of TMX1 in tumors (Panel EV5 D)(249), while one of the clue points to 
that the re-wiring of AKT signaling pathway is a potential mechanism of adaptation (Panel 
EV5 E). The tuning of signaling pathways in cancer cells is frequently observed and very 
complicated, so any concrete conclusion on this topic needs a further and thorough dissection 
via bioinformatics, large scale proteomics study, which are out of the main aims of this study 




Figure 25: Melanoma tumor growth is affected following TMX1 silencing. (A) The tumor 
volume monitored from 0~20 days after the inoculation with TMX1-silenced WM3734 cell 
on immune deficient mice. (B) Quantification of tumor volume data at day 20th. Data are 
presented as mean±SEM of 7 mice for each group. (C) The tumor volume monitored from 
0~45 days after the inoculation with TMX1-silenced WM3734 cell on immune deficient mice. 
(D) Quantification of tumor volume data at day 45th. Data are presented as mean±SEM of 7 
mice for each group. 
*The establishment of TMX1 stable knockdown cell line is done by Xin Zhang. The xenograft 
experiment, sample collection and stats collection were done by a joint effort of Xin Zhang, 
Dr. Adina Vultur, Dr. Christina Körbel. Data analysis and presentation were done by Xin 






































































































































8.1 The TMX proteins and NFAT1 are upregulated in melanoma and 
correlate with melanoma progression 
As presented in the results section, our analyses on the expression of TMX1, TMX3 and 
NFAT1 suggest their general upregulation in melanoma cell lines. These results also show 
that NFAT1 is the predominant NFAT isoform and indicated the existence of NFA1 positive 
and NFAT1 negative melanoma cell lines. Accordingly, our data are in line with previous 
studies, which suggest important role for NFAT in cancer (232, 233).  
To further examine the expression of TMX1 and NFAT1 in a clinical perspective, the 
immunohistochemistry staining (IHC) of healthy skin and melanoma patient biopsies were 
performed by our collaborators in the dermatology department. As indicated from their result 
(Panel 1D)(249), in a primary nodular melanoma sample, the healthy melanocytes only 
express a relatively low level of TMX1 while the melanoma cells express TMX1 proteins on a 
much higher level. In the healthy tissue including the basal layer and epidermal keratinocytes, 
the expression of NFAT1 protein is not detectable while the expression in the melanoma cells 
is significantly higher. The staining from the second case also showed a similar pattern of the 
expression which confirmed that the TMX1 and NFAT1 are expressed on a higher level in the 
melanoma patient-derived cells (Panel EV1C). 
Along with the progression of cancer, the up-regulation of proteins could be activated 
temporarily to facilitate the proliferation of the tumor or provide survival advantages such as 
immune escape, resistance to apoptosis or a pro-aggressive phenotype switch. This up-
regulation could also be constant to keep signaling pathways hyper active in the tumor cells 
and thus circumvent environmental stress factors. Therefore, it is important to examine if the 
expression of TMX1 and NFAT1 correlate with the progression i.e. aggressiveness of 
melanoma. For this purpose, the immunohistochemistry staining was performed also on a set 
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of tumor samples collected from the patients in various stages of melanoma progression. 
These samples included tumors with thickness less than 2 mm, aggressive tumors (thickness 
more than 4mm) and metastatic melanoma. To make comparison, the protein abundance in 
healthy skin, benign naevus and melanoma in situ were also examined.  As shown from these 
results (Panel 1E)(249), the abundance of TMX1 is at the lowest level in the healthy 
epidermis and melanocytic naevus (P1~P2); the in situ tumor samples show only a moderate 
expression (P3~P4). However, the expression increases with the growing thickness of the 
melanoma tumor (P5~P10). The tumors with a thickness more than 4 mm clearly show the 
highest expression of TMX1. Over all the metastasis (P11~P13) show the highest expression 
among all patient samples.  
On the other hand, the abundance of NFAT1 is nearly not detectable from either the healthy 
epidermis, naevus or the in situ melanoma (P1~P4). In 2 out of 3 tumors with a thickness 
more than 2 mm, the NFAT1 expression was not detected (P5~P6), but in the 3rd case only 
moderate NFAT1 levels were detected (P7). However, in the more advanced cases with 
thickness more than 4mm and especially in the distant metastases, the abundance of NFAT1 
becomes very prominent (P8~P13). Hence, based on the analysis of these 13 patient samples, 
we conclude, that the TMX1 and NFAT1 expression correlate with the development and 
invasiveness of the tumor. 
Furthermore, an additional IHC set of patient samples based on melanoma staging also 
confirmed high expression of TMX1 in the aggressive melanomas including superficial 
melanoma, nodular melanoma, sentinel lymph node metastasis and balloon cell melanoma 
(Panel EV1D)(249). The results from patient samples show a frequent and significant increase 
of TMX1, TMX3 and NFAT1 expression in melanomas, which have a strong correlation with 
disease stage. These results emphasize the clinical importance of TMXs, NFAT proteins and 
the underlying mechanisms in human melanoma. 
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8.2 The TMXs regulate NFAT1 activation via ROS, not Ca2+ 
Based on the report from Sharma and colleagues (219), we learned that silencing of TMX 
proteins inhibits NFAT1 nuclear translocation; an indication for a functional link between 
ER-mitochondria contact sites, gene transcription and disease progression. Since depletion of 
the ER Ca2+ store is involved in SOCE, which is necessary in activating calmodulin-
calciuneurin-NFAT1 signaling cascade, we initially hypothesized that the TMX proteins can 
affect NFAT1 translocation through their influence on cytosolic calcium transients; a 
hypothesis that asks for experimental testing.    
Our data confirmed that the TMX proteins can regulate NFAT1 activation in melanoma cells. 
The knockdown of TMX1 and TMX3 inhibits NFAT1 translocation and the expression of 
downstream effectors such as IL-8 in melanoma cell lines. In the study by Sharma et al., the 
changes in cytosolic Ca2+ were identified as a driving factor for the regulation of NFAT1 
activation by septins, which prompted us to hypothesize that TMX1 and TMX3 can alter 
SOCE, probably by influencing STIM activation or ER-PM junctions i.e. STIM-ORAI 
coupling mechanism. It has been reported that the ER-PM junctions and ER homeostasis can 
affect STIM activation and STIM/ORAI coupling to control SOCE (260, 261). Nonetheless, 
the localization of TMX proteins is in the MAMs, which suggests that the TMX proteins 
might regulate SOCE by altering the mitochondrial calcium uptake (262, 263). However, to 
our surprise, our results did not show significant changes in SOCE after knockdown of TMX1 
and TMX3, a finding that ruled out the possibility of calcium being the major factor at play. 
This led us to examine other elements than cytosolic Ca2+ in regulating the NFAT1 
translocation.  
It has been reported that calcineurin has cysteine residues both in and around its catalytic 
center, which is a Fe–Zn pair (264). Calcineurin can thus be regulated by the oxidation of 
either the iron cluster at the active center or the cysteine residues near the pocket, which might 
108 
 
be important for the conformational stability of the catalytic site. Previous studies have shown 
that O2- and H2O2 can deactivate the calcineurin in T-cells and other cells (265-267). In 
addition, the superoxide dismutase as well as the reducing reagent DTT and the thioredoxin 
enzyme can reverse/protect the H2O2-induced deactivation of calcineurin (268, 269). 
Furthermore the calmodulin-binding domain of calcineurin contains methionine residue, 
which is also sensitive to oxidation and can thus affect the binding and activation of 
calcineurin (270). Based on these literatures, we suspected that ROS might be responsible for 
the inhibition of NFAT1 activation in TMX silenced melanoma cells. Thus, we first examined 
the cellular H2O2 levels and found that the knockdown of TMX1 or TMX3 resulted in a 
higher H2O2 concentration. The ROS molecules can play different functional roles depending 
on their concentration. In the lower range (from nanomolar to a few micromolar), H2O2 serves 
as a signaling molecule (271); however, if the concentration is high enough to cause oxidative 
damage to biological molecules in the cells, ROS are toxic and can lead to cell death and 
malignant transformation (272). 
Thus, through a series of NFAT1 translocation assays combined with manipulations of 
extracellular H2O2 concentration we found that, in melanoma cells, NFAT1 activation was 
redox-regulated. Our data suggest that even in the micromolar range, H2O2 inhibits NFAT1 
activity; additionally, the NFAT1 inhibition caused by knockdown of TMX proteins could be 
reversed by antioxidants and reducing agents. These data indicate that TMX1 and TMX3 
might have a protective role by reducing cellular oxidative stress in melanoma cells. To 
understand the molecular mechanism of TMX knockdown induced NFAT1 inhibition, we 
examined the influence of TMX1 and TMX3 knockdown on calcineurin activity in melanoma 
cells. We found that its activity was suppressed upon knockdown of TMX proteins. In 
summary, our study suggests the knockdown of TMX proteins leads to a higher ROS levels in 
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melanoma cells, which are responsible for the inhibition of NFAT1 translocation via 
inhibition of calcineurin.  
 
8.3 The TMXs influence mitochondrial ROS production 
Based on the known functions of TMX proteins, the possible sources of ROS upon their 
silencing might be as follows: 1) ER lumen, due to disturbances in the redox homeostasis i.e. 
ER stress; 2) ER-based NADPH oxidases such as NOX4; 3) Mitochondria, through the ER-
mitochondria contact sites, the TMX proteins may influence the ROS generation in these 
organelles (273-275). However, our data indicate that the knockdown of TMX1 does not 
induce neither the expression of typical ER stress markers, nor higher level of ROS in ER. 
These findings suggest that the role of TMX proteins in ER stress is probably context-
dependent; and other oxidoreductases in the ER might be up-regulated to compensate for the 
loss of TMX proteins. Nonetheless, based on these negative results from investigation on ER, 
we started to investigate on the other targets.  
The NADPH oxidase 4 is involved in ER stress-related oxidative stress (276). And it has also 
been reported that TMX3 is an interaction partner of NOX4 (277). Thus, it is intriguing to 
identify whether NOX4 is relevant to the elevated ROS generation induced by the knockdown 
of TMX proteins. Our H2O2 measurements in melanoma cells upon TMX1 and NOX4 
silencing indicate a certain contribution of NOX4 but also suggest that ROS are generated by 
additional sources. Concerning the importance of NOX4 in melanoma (278, 279), further 
investigation in this direction will be interesting.  
Based on these findings we tested the mitochondrial parameters and found that the 
mitochondrial H2O2 levels were dramatically increased after the knockdown of TMX proteins. 
The mitochondria are the major source of ROS in the cells, considering the special 
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localization of TMX proteins, these data are not surprising to us. As mentioned previously, 
mitochondrial ROS production is closely coupled to the respiration and metabolism activities, 
and the measurements in these two parameters also in turn should confirm that the 
mitochondria are energized to produce higher level of ROS. These data thus led to questions 
concerning the mechanism through which TMX proteins regulate mitochondrial ROS 
production and metabolism.  
 
8.4 The ER-mitochondria contact sites shape mitochondrial dynamics 
Mitochondrial metabolism, Ca2+ and redox signaling are intrinsically integrated into a 
complex system for the regulation of cellular functions. Since the TMX proteins are localized 
in the MAM, their absence might cause consequences for both the structure and the function 
of ER-mitochondria contact sites, thus has a profound impact on the mitochondrial function.  
Our first clue, the elevated mitochondrial ROS, indicates that the mitochondrial metabolism is 
affected by the knockdown of TMX proteins. Thus, we next investigated mitochondrial 
calcium uptake in TMX silenced cells. Our data indicates that mitochondrial calcium uptake 
is increased in both the stable TMX1 knockdown cells and cells with transient silencing of 
TMX1 following activation of SOCE. The two major sources of calcium i.e. the ER and the 
cytosol, contributed in different ways: The ER-to-mitochondria calcium transfer was 
decreased, whereas the PM (cytosol)-to-mitochondria calcium transfer was increased 
significantly. Further measurements of cellular oxygen consumption and mitochondrial ATP 
production supported our findings and confirmed that increased calcium uptake led to higher 
respiratory activity. Thus, we investigated the mitochondrial morphology and the 
mitochondria positioning to the PM with confocal and electron microscopy in melanoma cells. 
The data indicates that the total volume and surface area of mitochondria are increased in 
melanoma cells with stable knockdown of TMX1. Moreover, the mitochondria are re-
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positioned to the PM proximity, which may lead to greater exposure of mitochondria to PM-
related events.   
The mitochondria and the ER are two major endomembrane systems in eukaryotic cells, and 
they form an extended reticular network. The ER-mitochondria contact sites, as mentioned 
previously, mediate signaling, lipid exchange and calcium handling to regulate many 
mitochondrial functions, including metabolic activity, replication and apoptosis (280, 281). 
Recent studies have revealed that the mitochondria can form contacts with other organelles, 
such as the PM, lipid droplets, vacuoles, lysosomes and peroxisomes (282). These studies lead 
to a broader understanding of the roles of mitochondria in cellular functions, and also suggest 
that the interactions of organelles via the contact sites may have profound influences on 
mitochondrial behavior (283). In such a context, the exact architecture of the contact sites are 
very important determining factors (284). Endoplasmic reticulum-mitochondria contact sites 
have been reported to be 10~30 nm wide (198) and are tethered by specialized membrane 
proteins in mammalian cells. Moreover, approximately 10 % of the PMs in cells are in contact 
and are anchored to mitochondria. The disruption of these anchors can redistribute the 
mitochondria away from the PM (285, 286).  
In previous studies, either the ER-mitochondria or PM-mitochondria contact sites were 
investigated alone. And their impact to the relative distance between organelles, 
mitochondrial division and distribution were clarified mostly in a yeast model (285, 287, 288). 
Based on our data, it is plausible to speculate that, together, these two elements determine the 
apposition of mitochondria relative to the ER and the PM. Under normal conditions, in the 
presence of TMX proteins, the ER-mitochondria contact sites are intact and the ER-to-
mitochondria calcium transfer is sufficient for normal cell function meaning that the 
mitochondrial ROS generation is under control and thus, the NFAT1 signaling pathway is 
active. However, if the ER-mitochondria contact sites are disrupted by the loss of TMX 
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proteins, the mitochondria will become more closely associated with the PM and more 
distanced from the ER. This will lead to increased mitochondrial calcium levels, which will 
further promote mitochondrial respiration and contribute to excessive ROS generation. The 
elevated ROS can then cause NFAT1 inhibition, thus resulting in a negative impact on 
melanoma cell biology. Our model is in agreement with a previous study that demonstrates 
that cancer cells are vulnerable to the inhibition of ER-mito calcium transfer (289) and recent 
findings concerning the protective role played by TMX1 during oxidative stress (290). Based 
on these evidences, at this point of the study, we conclude that the TMX-ROS-NFAT1 axis 
plays an important role in melanoma cell pathobiology. 
 
8.5 TMXs and NFAT1 promote aggressive melanoma phenotypes 
From the expression analysis, we had already learned that the TMX proteins and NFAT1 were 
upregulated in human melanomas and that their upregulations were relevant to the 
progression of the disease. Thus, we examined the proliferation and migration of melanoma 
cells upon the silencing of TMX proteins and NFAT1. Our data reveal that the knockdown of 
TMX1/3 or NFAT1 leads to inhibition of both proliferation, migration and invasion of 
melanoma cells in vitro. Notably, the pharmaceutical inhibition of calcineurin and NFAT1 
elicits similar effects. Furthermore, the TMX1 knockdown suppresses the growth of tumors in 
a xenograft mouse model although the tumor cells can adapt by activating AKT and probably 
also re-wiring other pathways. These data indicate that the attrition of TMX proteins and 
NFAT1 has a negative impact on melanoma cells; a finding which confirmed our hypothesis 
regarding the role of mitochondrial contact sites on melanoma pathology.  
Yet the results so far indicate that TMX1, TMX3 and NFAT1 play important roles in 
melanoma cell pathobiology. To explore the connection in human patients and prognosis of 
melanomas, the integrative bioinformatics analysis was performed by our collaborators, 
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Thorsten Will and Prof. Dr. Volkhard Helms. By analyzing the Cancer Genome Atlas (TCGA: 
https://cancergenome.nih.gov/) database and focusing on the correlation between the mRNA 
expression levels of TMX1, TMX3 and NFAT1 and the survival of patients with cutaneous 
melanoma, their analysis indicates that the high expression of any of the three target genes, 
TMX1, TMX3 and NFAT1, correlates with a significantly decreased survival expectancy 
compared with patients with low expression (Panel 7A)(249). The further analysis shows that 
the high expression of TMX1, TMX3 and NFAT1 also has a negative impact individually on 
the survival probability of the melanoma patients (Panel EV5J, K, L).  
To further identify the impact of TMX proteins and NFAT1 on survival of melanoma patients 
with different BRAF mutation status, the correlation between the expression of TMX1, 
TMX3, NFAT1 and BRAF status in a cohort of 97 melanoma patients, which consisted of 49 
WT and 48 BRAF V600E melanomas were analyzed. The results (Panel 7B)(249) show that 
the expression of TMX1/TMX3 is not correlated to the mutational status of BRAF, while the 
expression of NFAT1 is significantly increased in patients with BRAF V600E mutation. In 
patients with BRAF V600E mutation, the high expression of NFAT1 does not affect survival 
probability (Panel 7D). However, the high expression of NFAT1 significantly reduces the 
survival probability of patients with BRAF WT status (Panel 7C).  These data suggest that the 
TMX-ROS-NFAT1 signaling axis has a more prominent effect in BRAF WT patients, a 
finding that might be considered in choosing the therapeutic approaches for melanoma 
patients.  
Based on the melanoma patient data and the bioinformatics analysis, it is plausible to 
conclude that the high expression of TMX and NFAT1 are correlated to an aggressive 
melanoma phenotype and enhanced melanoma progression; and the experimental data shows 
their strong impact on intracellular redox regulation and mitochondrial bioenergetics. Given 
that the influence of this signaling axis is mediated by the regulation of NFAT1, the target 
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genes of NFAT1 in melanoma cells are of particular interest. To further identify them, two 
independent published studies, which evaluated the transcriptome of melanoma cells 
following knockdown of NFAT1 using different approaches (242, 259) were analyzed. It was 
identified that there were 59 upregulated genes and 56 downregulated genes after NFAT1 
knockdown in melanoma cells (List of individual genes published as Table S5)(249).  
To address the functional relevance of these genes, the associated annotation data by the Gene 
Ontology Consortium (www.geneontology.org) were used for further investigation. The fold-
enrichment of genes with different term annotations defined by their background indicates 
that NFAT1 controls two major groups of genes in melanoma cells, “Mitochondrion-localized” 
and “Redox-related” (Panel 7F)(249). Furthermore, the fold-enrichment calculations of the 
transcriptomic data were categorized by the “Hallmarks of cancer”, and the results show that 
most of the genes under NFAT1 control can be assigned to the hallmark “Deregulating 
Cellular Energetics”.  In addition, the data show that the hallmarks such as cell death 
resistance, inflammation, evading growth suppressors and immune destruction, proliferation 
and invasion are also regulated by NFAT1 (Panel 7G).  
These analyses confirm our experimental findings and suggest that NFAT1 can influence the 
cellular redox state by regulating mitochondrial function, thus supporting melanoma cell 
aggressive phenotype and ultimately lead to lower survival expectancy of melanoma patients. 
Thus, we conclude that TMX proteins and NFAT1 are pro-tumorigenic and their expression 




8.6 The TMX-NFAT1 axis regulates mitochondrial function and redox 
homeostasis in melanomas 
In our model, the TMX proteins determine the integrity of ER- mitochondria contact sites and 
thus control NFAT1 activity by modulating the intracellular ROS level. Previous studies have 
suggested that mitochondrial Ca2+, mitochondrial respiration and ROS generation can regulate 
NFAT activation in different models. In neuron cells, mitochondrial calcium uptake can 
prolong the activation of PM channels to sustain the calcium influx, which is important for 
NFAT1 activation (291). The low levels of ROS produced by the mitochondrial respiratory 
chain during sustained SOCE can also activate NFAT in T-cells and embryo cells (292-294). 
Based on our findings and the literature, we were able to implement the redox regulation of 
NFAT1 in our model. Here, we suggest that, in healthy cells, intact ER-mitochondria contact 
sites can provide normal calcium transfer to the mitochondria so mitochondrial ROS 
generation is in control, the normal NFAT1 function is unaffected and can be activated readily. 
As a protective feedback loop, the excessive ROS generated by abnormal metabolism activity 
can inhibit NFAT1 activity, which will lead to reduced mitochondrial activity and lower ROS 
production. In melanoma cells, the high expression of TMX proteins enhances the stability of 
the ER-mitochondria contact sites, while the high expression of NFAT1 increases the 
mitochondrial capacity to provide more energy to support cancer progression. Simultaneously, 
the upregulated antioxidant system manages redox balance to prevent negative effects (Graph 
5, left). However, the knockdown of TMX1 protein level will disrupt the integrity of ER-
mitochondria contact sites, thus causes an over-exposure of mitochondria to PM and calcium 
influx via channels on it. This will lead to increased mitochondrial Ca2+ uptake and excessive 
ROS generation, in turn, the ROS can deactivate NFAT1 signaling by inhibiting Calcineurin 




Graph 5: Theoretical Model of the TMX-ROS-NFAT1 Signal Axis in Melanomas. 
*This conceptual figure is modified from our publication “Redox signals at ER-mitochondria 
interface control melanoma progression”, Zhang et al, EMBO J. 2019 Aug 1;38(15): 
e100871.  
 
8.7 ER-mitochondria contact sites and the TMX-ROS-NFAT1 axis in the 
perspective of melanoma therapeutics 
As noted in the above discussion of our model, our study suggests that the TMX-NFAT1 
signaling axis, which contributes to the progression of human melanoma, is tuned by redox 
signals generated at the ER-mitochondria interface. These findings illustrate the importance of 
the ER-mitochondria contact sites and TMX-ROS-NFAT1 in melanoma pathology. Thus, it is 
important to discuss the possible implications of these findings from a clinical perspective.  
The research on ER-mitochondria contact sites is still an emerging field regarding cancer 
biology despite the several recent discoveries. ER-mitochondria communication governs 



































plasticity, apoptosis, autophagy and inflammation (273, 295). Hence, any aberration on its 
part is associated with pathological conditions including cancer, Alzheimer’s (296), obesity 
and diabetes (297). However, as a functional platform, the structural support provided by the 
contact sites for the morphology and distribution of mitochondria in cancers, including 
melanoma, has not been explored thoroughly, perhaps due to the difficulties in targeting it for 
therapeutic purposes. Nonetheless, our work suggests that, by manipulating the ER-
mitochondria contact sites, downstream mitochondrial ROS generation can be elevated and 
causes inhibition of transcription factors such as NFAT1. This can ultimately lead to the 
suppression of aggressive melanoma, which might be of clinical interests.  
As mentioned previously, the ROS molecules are involved in the formation, metastasis and 
drug-resistance of melanoma. Abnormal intracellular sources of ROS in melanoma might be 
aberrant melanosomes, irregular metabolic activity and NADPH oxidases. In cancer cells, it is 
very commonly that the antioxidant system is upregulated to cope with the increased ROS 
levels (131). Mitochondria as a major endogenous source of ROS have been linked to cancers 
including melanoma for a quite long time; previous studies have explored their implications 
for therapeutics (298, 299). Recently, a series of studies have identified mitochondrial 
metabolism as an important mechanism for the drug resistance of melanoma (143, 189, 192) 
and have also highlighted targeting mitochondrial oxidative stress as a potential strategy for 
addressing drug resistance (158, 300). Our study is in agreement with these findings, and 
suggests that, in melanoma cells, the mitochondrial ROS can be induced to inhibit critical 
phosphatases, which could further deactivate downstream pathways such as NFAT1 signaling. 
Since the expression of the TMX proteins are not correlated to BRAF status in melanoma, 
their knockdown will trigger general ROS responses which may induce detrimental effects in 
melanomas regardless of their BRAF status. Additionally, as a responding factor, NFAT1 
118 
 
displays a prominent effect in the patients with BRAF WT phenotype and could thus be 
targeted for treatment in the sub-population of melanomas.  
Studies concerning the role of calcineurin/NFAT1 in melanoma are scarce, although most 
have noted that NFAT1 expression is related to melanoma growth and metastasis (242, 301). 
Calcineurin has been frequently discussed in the context of Ca2+ signaling (302, 303); its 
inhibition has been reported to have multiple effects on human melanoma (247). It is 
interesting to note that the expression of calcineurin is also correlated with the malignancy of 
melanoma and mitochondrial activity in the study conducted by Juhasz and colleagues. 
Although the inhibition of calcineurin by CsA was found to have different effects on the 
migration of melanoma cell lines, which can perhaps be attributed to different NFAT levels. 
Notably, a study on fruit flies stated that calcineurin played a critical role in maintaining 
metabolic homeostasis, mitochondrial morphology and activity, although, as the downstream 
effector, NFAT was not in the focus of this research (304). It is likely that calcineurin affects 
mitochondrial activity through NFAT1 signaling, but a detailed dissection of 
calcineurin/NFAT1 signaling network will be required to understand the various effects 
induced by the inhibition of the NFAT1 activation. Overall, our findings emphasize the 
potential of targeting redox-based processes in melanomas and indicate that 
calcineurin/NFAT1 may be crucial for the regulation of mitochondrial activity. To this end, 
additional studies are needed to explore the opportunities for targeted therapeutics against 
melanoma.         
 
8.8 Conclusion 
Melanoma is a cancer caused by various genetic as well as environmental factors. The 
heterogeneity of melanoma is a reflection of aberrations in signaling pathways caused by 
mutations, which lead to a reprogrammed metabolic activity, abnormal proliferation and 
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migration. In this study, we explored the importance of ER-mitochondria contact sites in the 
pathology of melanoma and dissected a novel redox-driven ER-mitochondria-NFAT1 
signaling axis that integrates mitochondrial calcium transfer, bioenergetics and cellular redox 
homeostasis and contributes to melanoma progression. Our work suggests that ER-
mitochondria contact sites can shape calcium and redox signaling in favor of tumor 
progression, whereas their alterations can in turn limit melanoma proliferation and migration. 
Accordingly, TMX1, TMX3 and NFAT1 are potential melanoma progression biomarkers as 
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